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Angiogenesis, defined as the formation of blood vessels from pre-existing vessels, 
is an important natural process. While angiogenesis does not occur in healthy mammals. it 
plays a major role in tumor development and wound healing. The tightly controlled process 
of angiogenesis is dependent on a variety of biochemical and biomechanical cues. Using 
synthetic bioactive hydrogel systems allows us to investigate this well controlled process. 
For instance, many have adapted three dimensional (3D) tissue culture models that 
recapitulate aspects of the tumorogenic in vivo microenvironment to study cancer 
progression in vitro and its linkage with angiogenesis. At the same time, a 3D tissue culture 
bioactive scaffolds can also provide a therapeutic strategy to treat various injuries and 
diseases. 
First we utilized hyaluronic acid hydrogel systems and using mathematical 
modeling, found that varying viscoelasticity in atmospheric and hypoxic environments 
affects cancer cell cycles and the expression of autophagy and apoptosis genes. Hypoxic 
stress enabled greater recovery from apoptosis through autophagy mechanism and induced 
greater angiogenic leading to extensive endothelial cell (EC) sprouting. Next we used the 
same hyaluronic acid hydrogel engineer human microvasculature for the treatment of 
diabetic foot ulcers (DFUs), one of the leading healthcare problems in the US.  To this end, 
we developed an immunodeficient diabetes rodent DFU model. Treatment of DFU with 
engineered human vascularized hydrogel scaffolds from stem cell derived vascular cells, 
has shown faster wound healing compared to acellular hydrogel, thus suggestion a potential 




hydrogel system to induce vascularization and healing of third degree burn injuries in a 
large animal model. We have observed accelerated third degree burn wound healing in 
porcine by rapid wound closure, improved re-epitheliazation, enhanced extracellular 
matrix remodeling and greater nerve re-innervation in the hydrogel treated wounds.  
 Collectively, the results from this thesis showcase the successfully utilization of 
bioactive hydrogel scaffolds to study various biochemical and biophysical cues that 
influence angiogenesis. Combing with stem cell technologies, the hydrogel systems can 
improve wound healing at both diseased and severe skin injuries.   
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1.1 Biomaterials for Tissue Engineering and Regenerative Medicine 
Tissue engineering (TE) and Regenerative medicine (RM) have the goal of 
developing a biological substitute that repairs, improves, or maintains the original tissue 
function. One factor limiting the field is the provision of well-vascularized constructs for 
nourishment of rapidly proliferating cells. The cell microenvironment consists of the 
noncellular extracellular matrix (ECM) and the biological molecules which it sequesters, 
as well as the vascular networks. The ECM provides a living space for cell proliferation 
and differentiation. Biosignaling molecules sequestered in the ECM serve as messengers 
to direct cell fate (e.g. growth and differentiation of stem cells and proliferation, 
differentiation and tube-formation from ECs). Vascular networks provide a means of 
supporting nutrition (e.g. glucose and O2) and removing waste (e.g. CO2) in the tissue.  
Because of limitations of oxygen diffusion, cells cannot survive when they are located 
greater than 150 µm away from the nearest capillary [1]. Without a steady supply of 
nutrients, cells in the constructs will not survive in-vivo.  Thus, engineering a vascularized 
construct is an essential step for the successful regeneration of a tissue of interest. 
Several design criteria must be addressed in order to engineer a vascularized 
construct.  The material should: 1. Be biocompatible to the host (i.e. the material must 
provide a favorable surface for cell attachment and proliferation). 2. Be biodegradable; the 




through waste removal systems such as urine. 3. Provide enough mechanical strength in 
order to withstand surgical implantation and the mechanical stresses imposed by the body 
itself. 4. Retain a porous structure so that it not only provides sufficient space for cell 
migration and proliferation, but also allow the encapsulation and delivery of various 
biosignaling molecules.  
1.1.1 Biocompatible scaffolds for the generation of vascular structures  
Weinberg and Bell were the first to document the design of vascular biomaterials. 
They formed a vascular conduit initially comprised of smooth muscle cells (SMCs) seeded 
in a collagen gel [2]. Fibroblasts were later added to the outer rim of the vessel, ECs were 
added to the interior of the vessel and a polytetrafluoroethylene (Dacron) graft was 
introduced to provide additional mechanical strength to the newly synthesized vessel [2]. 
The artificially created vessel possessed differentiated ECs and produced bioactive 
molecules [2]. Following this discovery, other investigations employed a variety of both 
natural and synthetic materials to generate vascular conduits both to replace diseased 
arteries and to expedite the generation of vascular structures for tissue regeneration.  The 
biomaterials utilized to design such vascular constructs are discussed below.   
1.1.1.1 Biomaterials inspired by the ECM  
The construction of vascular biomaterials depends on the ability of the cell 
population of interest to deposit a long-term layer of ECM. Living organisms produce a 
variety of polymers, which can be categorized into three groups: polysaccharides, proteins, 
and polyesters. Due to the advances in biotechnology, most of these polymers can be 




plants, animals or algae.[3]. Below, we describe the various biomaterials used to mimic the 
natural environment of ECs. 
Collagen, the most abundant protein in the body, belongs to a family consisting of 
more than 20 genetic splice variants. Collagen gel exhibits shear-thinning behaviors, which 
means its viscosity decreases as the applied shear increases [4]. Due to collagen’s fibrous 
nature, collagen networks usually require secondary mechanisms to produce scaffolds that 
can withstand the mechanical stresses induced by encapsulation or TE procedures [5].  
Thus, collagen can be cross-linked with a PEG-based polymer. One group found that 
chondrocytes encapsulated in such a scaffold remained viable three weeks following 
encapsulation [6]. Another group copolymerized collagen with dextran in order to mimic 
tertiary embryonic connective tissue, which demonstrated improved tissue growth into the 
scaffold [7]. Lastly, synthetic vascular structures have been designed by embedding 
collagen and dermatan sulfate into prosthetic scaffolds, followed by the addition of 
fibroblasts or SMCs and ECs [8]. This approach yielded patency rates of 80 percent as long 
as twenty-six weeks following grafting into animal common carotid arteries [9]. 
 Hyaluronanic acid (HA), a linear glycosaminoglycan which is soluble in water, 
can readily form hydrogels. Hyaluronidase, which exists in cells and serum, degrades it 
enzymatically.  Much of the attention devoted to HA is due to the following HA chemical 
properties, among others that it can be: 1. obtained in a wide range of molecular weights 
(by hyaluronidase degradation); 2. enzymatically remodeled by selected cell types, such as 
chondrocytes; 3. functionalized with reactive group to form hydrogels; and 4. modified to 
adjust its cell-adhesive properties [10]. It is possible to control the degradation rate and 




additionally developed flat sheets of non-woven HA-based scaffolding as vascular grafts 
[12]. One group also showed that HA degradation products have proangiogenic activities 
[13]. Finally, HA-based scaffolds correlate positively with the successful treatment of 
osteochondral defects [14]. 
Fibrin is a major component of blood clots and plays an important role in 
spontaneous tissue repair. It forms a temporary network by polymerization of fibrinogen 
through the presence of the enzyme thrombin.  Clinically, fibrin is used as a glue in surgical 
procedures.  Fibrin can serve as an efficient vehicle for the delivery of growth factors or 
biomacromolecules [15].  It has also been used to regenerate skin and in the loading and 
release of growth factors [16]. Alternatively, fibrin scaffolds can serve as provisional 
reservoirs for the delivery of therapeutic proteins or cells for TE [17]. 
Alginate, a natural hydrophilic polysaccharide derived from algae, can be cross-
linked in a gel with the use of divalent cations, such as Ca2+and Mg2+.  The shape and 
strength of the gels in calcium-rich solutions can be altered [18]. Because of its hydrophilic 
nature, it can promote cellular proliferation with a homogeneous cell distribution within 
the scaffold.  One author of this chapter was part of a group that effectively employed 
capillary action to pull human embryonic stem cells (hESCs) into an alginate scaffold [19]. 
Additional applications include injectable cell delivery vehicles [20] and alginate 
hydrogels used for cartilage TE [21]. Alginate gels can also serve as delivery vessels for 
proangiogenic growth factors necessary for the treatment of ischemia. 
Chitin can be found in animal shells and exoskeletons of insects. It is insoluble in 
most common solvents but can be chemically modified into soluble derivatives, such as 




in blood serum. The properties of porous chitosan matrices can be varied by altering the 
chitosan concentration, freezing rate, and molecular weight. It is also utilized for the 
controlled release of pharmacological agents and as an effective nonviral vector for gene 
delivery [23]. It can also be engineered into sponge-like scaffolds in bone formation and 
cartilage TE [24].  
Dextran, a bacteria-derived polysaccharide, has been used as a potential biomaterial 
for TE. It is soluble in both water and organic solvents. Its chemical structure consists of a 
large number of hydroxyl groups, which are available for chemical modification. Such 
modifications are necessary since dextran is naturally resistant to cell adhesion and is used 
as a biomaterial surface coating to limit cell adhesion. Functional group modifications can 
also alter its chemical and physical properties [25]. As a result, researchers have observed 
different vasculature responses.  Lastly, by incorporating a cell adhesion peptide, one group 
showed that dextran, modified with Arg-Gly-Asp (RGD) peptides, promoted EC adhesion 
and spreading [26]. 
Natural polymers are found in the living organism and are appealing for the design 
of biomimetic scaffolds, since they are inherently biocompatible and can be enzymatically 
degraded. For example, native, tissue-derived ECM may be harvested from small intestinal 
submucosa (SIS), umbilical veins, cadaveral arteries [27] and even xeno-geneic materials 
such as porcine aortas, common carotid arteries, iliac arteries and bovine ureters. The use 
of such natural materials is highly desirable since native ECM possesses the appropriate 
spatiotemporal features [28], and acts as a natural reservoir for proangiogenic  molecules,  




associated with the use of natural matrices are their susceptibility to enzymatic digestion, 
their propensity for thrombus formation, and their decreased mechanical strength. 
1.1.1.2 Biomaterials from synthetic sources 
Due to present limitations in the application of natural ECM for the fabrication of 
vascular constructs, other strategies are being developed and investigated. One strategy 
uses biodegradable (biomimetic) scaffolds to direct the synthesis of vascular structures.  
Interestingly, when compared to naturally derived polymers, synthetic materials have 
captured more attention in the recent years. Investigators have increasingly relied on 
scaffolds made of artificial materials to take advantage of the versatility and functionality 
that they provide [31]. Most synthetic polymers have the advantage that they are degraded 
via chemical hydrolysis and are insensitive to enzymatic processes, which limits variation 
among batches. 
The most frequently utilized biodegradable scaffold is polyglycolic acid (PGA), 
since it is not only pliable and thus can be formed into a multitude of shapes, but it is also 
highly porous, allowing the diffusion of oxygen and nutrients necessary to facilitate 
angiogenesis.143 PGA, which consists of monomers linked by ester bonds, can easily be 
degraded to glycolic acid by water through hydrolysis, both in-vitro and in-vivo. In 
addition, it is hydrophilic in nature, resulting in its tendency to lose mechanical strength 
rapidly over a period of weeks and becoming fully absorbed within a few months [32]. Its 
controlled rate of degradation allows cells to deposit ECM and, in so doing, permits them 
to establish themselves within their own microenvironment [33].   
Polylactic acid (PLA) is structurally similar to PGA; however, PLA and PGA have 




can exist in two forms, PLLA or PDLLA. The former is more widely used since L-lactic 
acid occurs naturally; however, it is more hydrophobic compared to PGA.  As a result, its 
degradation half-time (i.e., from months to a year) is much longer than PGA [34]. Some 
studies have indicated that neither PGA nor PLA may actively provoke an immune 
response since they pack peptide bonds [35].  The mechanical and degradation profile of 
the scaffold can be controlled by creating a copolymer of PGA and PLA (PLGA). 
However, PLGA’s characteristic property is not always a linear correlation with the pure 
polymer. For example, PLGA containing equal ratios of PGA and PLA degrades faster 
than a pure PGA scaffold [32]. The hybrid scaffold was developed to differentiate hESCs 
since it facilitates cellular adhesion, proliferation, and viability [36].  
Polyethylene glycol (PEG) is a hydrophilic polymer the native structure of which 
does not permit cellular adhesion. It does, however, contain one hydroxyl group at each 
end which can be chemically modified so as to facilitate cellular attachment. The reactive 
group on the PEG polymer can be cross-linked by UV irradiation to form a hydrogel that 
mimics tissue ECM.  Additionally, the chemically modified hydrogel can incorporate 
bioactive molecules in order to direct cell fate. For example, in-vivo studies demonstrated 
that a VEGF-conjugated hydrogel prompted the local release of VEGF, which, in turn, 
promoted EC survival, growth, and concomitant vessel formation [37].  Using PEG 
polymers has the advantage that they can be easily cleared by the kidneys [38]. Due to their 
high hydration content, PEG gels can also act as a barrier to macromolecules involved in 
immune responses [39].  For instance, One group found that PEG gels provided a 




[40]. Another group also reported that ECs cultured in a modified PEG hydrogel organized 
into stable, intricate networks of capillary like structures (CLSs) [41]. 
1.1.2 Biomaterials modification 
It’s important to consider cell-matrix interactions in natural ECM. In order to truly 
mimic the natural ECM, the aforementioned biomaterials require additional surface 
modifications. Modifying their surfaces with bioactive molecules is a simple way to make 
biomimetic materials.  Earlier studies using two naturally occurring ECM components, 
fibronectin and laminin, to coat biomaterials, yielded improved cell adhesion and 
proliferation [42]. With recent advances in synthetic biology, active peptide chains on the 
long ECM proteins have been identified; however, laboratories can produce short peptide 
chains in larger quantities and more efficiently. In addition, short peptide chains are more 
stable during the modification process than the original long-chain protein.  Moreover, the 
modified materials can be used in TE and can also serve as an artificial ECM, therefore 
providing suitable receptor-binding domains for cell attachment [43]. The biological cue 
that initiates the cell-signaling cascade as a result of cell-to-matrix interactions can be used 
to promote viability, to direct cell fate, and to guide 3D tissue formation.  One of the most 
commonly used peptide sequences for the modification of scaffolds is RGD, the active 
binding site sequence on fibronectin (Table 1-1). For example, to ensure covalent binding 
of the peptides to the surface, the surface amine reactive moieties were chemically reacted 
with the carboxyl functional groups presented within the bioactive peptide. A bifunctional 
cross-linker was used to immobilize the peptide to the surface [44]. Utilizing an RGD-




speeds were enhanced, thus potentially lessening the time required for ECs to organize into 
patent blood vessels [45]. 
 











Smooth muscle cell adhesion[46] 
Endothelial cell adhesion [47] 
Laminin IKVAV Neurite extension[48] 
Laminin B1  YIGSR Cell adhesion[48] 
Laminin B2 RNIAEIIKDI Neurite extension[49] 
Cell adhesion molecules KHIFSDDSSE Astrocyte adhesion[50] 
Elastin VPGIG Enhance elastic modulus[51] 
Heparin binding domain KRSR 
AGPL 
Osteoblast adhesion[52] 
Collagenase mediated degradation[53] 




1.1.2.1 Biochemical cue incorporation 
Surface modifications provide control over cell behavior; however, these 
modifications are limited because they are applicable for 2D structures rather than tissue-
specific 3D structures.  Bulk modifications are preferable in TE and RM applications. 
Several cell binding peptides have been introduced in 3D scaffolds through chemical[54], 
photochemical, [55], and ionic cross-linking [56]. For example, one group synthesized 
alginate-based hydrogels covalently coupled with RGD. The peptide-modified hydrogel 
promoted soft tissue augmentation in-vivo [57]. Also, another group demonstrated that 
hydrogels, fabricated with integrin binding sites and protease cleavage sites, not only 
promoted CLS formation but also recruited MSCs to mechanically stabilize the newly 
formed CLSs [41]. 
 
1.1.2.2  Biophysical cue incorporation 
The mechanical properties of biomaterial scaffolds are also important. For example, 
in living skin substitutes used clinically to treat burns, the tension generated by fibroblasts 
in the collagen scaffolds is essential for the production of constructs with adequate 
biomechanical integrity. The ability to modify such scaffolds via extrinsic mechanisms is 
highly desirable, as recent studies have indicated that stem-cell differentiation may be 
modulated by varying the stiffness of the scaffold [58]. For instance, researchers 
demonstrated that, following the application of cyclic tension, SMCs seeded in scaffolds 
could be effectively utilized to produce bypass grafts in vitro [59]. Aside from vascular 
engineering, scientists have also demonstrated that the growth of fasciculated axons can be 




application of mechanical tension, the physical properties of scaffolds may also be 
modified so as to facilitate cellular retention and proliferation. For instance, one group 
found that they could alter the local physical properties of scaffolds via exposure to a light 
source [61]. This study showed that the scaffold degraded following its exposure to light 
which, in turn, decreased its mechanical strength [61]. As a result of light-induced 
degradation, the scaffold-encapsulated MSCs exhibited enhanced cell spreading, a pre-
requisite for cellular survival and proliferation. A vascular engineering group found that 
vessel diameter was increased and vessel density decreased when EPCs were cultured on 
a stiff, more concentrated collagen gel [62]. 
 
1.1.2.3 Drug release strategies 
While scaffold architecture is important for promoting cellular attachment, 
proliferation and differentiation, the therapeutic efficacy of the cellular source is limited if 
the mitogens necessary for cellular proliferation are not present. Generally, the local 
injection of growth factors is not effective, because these biomacromolecules rapidly 
diffuse away from the injection site [63]. Thus, the local concentration of the injected 
growth factors cannot effectively facilitate the proliferation of the cells encapsulated in the 
scaffold.  In order to overcome this limitation, scaffolds should be designed so that the 
biomacromolecules are sequestered in the scaffold, but are also released in a steady state 
fashion to promote prolonged cell proliferation. Considering that most biosignaling 
molecules have a short life span and are unstable in-vivo, the scaffold should be designed 
to serve as a protective barrier against protease and/or immune degradation. In this way, 




degradation by the harsh physiologic surroundings. When the scaffold does degrade, 
whether through hydrolysis or enzymatic degradation, biosignaling molecules may be 
released, which may recruit surrounding cells, such as ECs, to contribute to the delivery of 
oxygen and nutrients to the rapidly proliferating cells.  
 
1.2 Blood vessels and vascular therapy 
1.2.1 Angiogenesis and vascular system 
The vascular system — the sole means for delivery of nutrients, water, oxygen, and 
proteins to tissues and for removal of wastes and other by-products — is essential for the 
proper functioning of tissue. During embryogenesis, blood vessels are optimally 
constructed, so that new formation of blood vessels (neovascularization) is rarely needed 
for adults in normal physiological condition. Neovascularization is commonly divided in 
two subcategories (Figure 1-1): vasculogenesis and angiogenesis. Angiogenesis is the 
formation of new blood vessels from pre-existing vessels, whereas vasculogenesis occurs 
in the absence of pre-existing vessels. Both occur in adult neovascularization, such as in 
the process of wound healing or during women’s ovarian cycle. But abnormal blood vessel 
formation can also occur during such pathologies as inflammation or tumors: chronic 
inflammation will induce angiogenesis in attempts at healing, while tumors will induce 






1.2.2 Stem Cells for regenerative medicine  
     Stem cells (SCs) are defined as clonogenic populations of cells capable of self-
renewal into additional stem cells and of differentiation into the various cell lineages [64]. 
Not all stem cells are alike, differing in their degree of plasticity. For example, totipotent 
stem cells (from fertilized embryos) can give rise to a functional organism; pluripotent stem 
cells (from the inner cell mass of the embryo) can produce all tissue types; and multipotent 
stem cells (from adult tissue stem cells) can generate a limited range of cells within a given 
tissue (e.g., blood and lymphoid cells in the hematopoietic system). As our understanding 
of these stem cell populations (briefly explored below) continues to grow, scientists are 
harnessing the seemingly unlimited potential of these once ambiguous cells for a wide array 
of therapeutic modalities. 
 




1.2.2.1 Endothelial progenitor cells (EPCs).  
There are studies have shown that EPCs, first derived from peripheral blood and 
from bone marrow, are the major factor in neovascularization: during postnatal 
vasculogenesis, EPCs circulate from bone marrow, incorporate into sites of 
neovascularization, and differentiate into ECs to form blood vessels [65]. Following these 
studies, EPCs were isolated from various sources: umbilical cord blood, the liver, tissue-
residing cells, or vascular walls themselves. Despite the proliferative potential of adult 
EPCs and other progenitor cells, several reports have indicated that a decline in the 
proliferation and differentiation abilities of these cells is associated with aging and chronic 
diseases[66]. 
1.2.2.2 Induced pluripotent stem cells (hiPSCs). 
     The field of stem cell technology was revolutionized when the discovery was 
announced that a patient’s terminally differentiated cells (somatic cells) could be re-
programmed to produce any cell type of interest [67]. Reportedly, such cells not only offer 
the advantage of supplying unlimited numbers of cells for patient needs, but perhaps more 
importantly, pose no threat to immune-mediated graft rejection since the cells are derived 
directly from the patient.  Such cells have been termed induced pluripotent stem cells (iPS), 
adult somatic cells which have been re-programmed to assume an ESC-like phenotype via 
introduction of either of two transcription factor sets:  Oct4, Nanog, Sox2, Lin28 or Oct4, 
c-Myc, Sox2, Klf4 [68]. The breakthrough discovery that terminally differentiated adult 
cells could be induced to de-differentiate into pluripotent stem cells intensified research 
into the use of such cells for the treatment of a wide array of diseases.  Using animal 




contractile function after experimentally-induced ischemia [69]. For instance, researchers 
discovered that iPS cell lines could be guided to form vascular structures through the use 
of methodology previously validated to direct the differentiation of hESCs into vascular 
cells [70]. It also reported that the iPS-derived vascular cells expressed EC-specific 
markers and organized into capillary-like structures (CLS) when cultured on Matrigel, an 
extracellular matrix (ECM)- rich material known to support the formation of CLS. 
Interestingly, a fraction of the vascular lineage-differentiated iPS cells were further 
differentiated into perivascular-like cells (e.g., SMCs) as evidenced by their expression of 
SMC specific markers α-smooth muscle actin (α-SMA) and calponin [70]. 
Stem cell-based therapy can be an approach to enhancing neovascularization. 
Biomaterial scaffolds are widely used to provide a three-dimensional (3-D) 
microenvironment for culturing vascular SCs in vitro and as their carrier for 
transplantation. The aim is to maximize angiogenic potential in the scaffold to mimic the 
microenvironment in nature. Modifications of the scaffold are necessary to ensure 




1.3 Merging Biomaterials science and stem cell technology for vascular 
regenerative medicine 
1.3.1 Vascularized constructs.  
There are two methods of vascularize a construct: extrinsic and intrinsic. In the 




design, cell sources, and culture environment. The scaffold is prevascularized ex vivo and 
is transplanted in vivo to encourage integration with the local vasculature. 
Prevascularization is mostly achieved by modifying the scaffold with extracellular matrix 
(ECM) proteins and peptides organized to guide angiogenesis. The intrinsic method utilizes 
several vectors (SCs or angiogenic factors) to direct local microvasculature to infiltrate the 
scaffold in vivo. 
While the cellular environment plays a key role in directing stem cell fate, the 
ubiquitous availability of oxygen and nutrients to drive sustained cellular proliferation and 
tissue growth is essential. Indeed, without the availability of oxygen and nutrients carried 
by red blood cells circulating within patent blood vessels, all attempts to regenerate a tissue 
of interest will be futile. Thus, researchers have focused designing biomaterials which 
facilitate the formation of blood vessels both in-vivo and ex-vivo. Appreciating the cellular 
components that comprise blood vessels must precede understanding what cell populations 
produce blood vessels and which biomaterials favor their growth. While variations exist 
depending on the type of vessel (i.e., artery, capillary or vein), all blood vessels have the 
same general structure: the tunica intima, the innermost layer of the blood vessel, is 
composed of endothelial cells (ECs) which line the lumen of the vessel; the tunica media, 
the middle layer of the blood vessel, comprises mural cells (pericytes and smooth muscle 
cells [SMCs]) which provide the vessel with its contractile and mechanical properties; and 
the tunica adventitia, the outermost layer of the blood vessel, comprises a variety of 
connective tissues and fibroblasts which provide the vessel with structural stability. Along 
these lines, biomaterials must be designed so as to favor the migration, proliferation, and 




must not only provide favorable attachment sites for ECs but must additionally possess 
pores of an appropriate size, quantity, and distribution to allow both the 3D migration and 
tube formation from ECs and the subsequent diffusion of oxygen and nutrients necessary 
to facilitate tissue regeneration [71, 72]. 
It is also well known now that cells inside the human body are in a 3D 
microenvironment. A scaffold can serve as a structural template for cell adhesion, 
proliferation, and differentiation or as a delivery vehicle for bioactive molecules during 
tissue assembly. A variety of both natural and synthetic materials have been developed to 
optimize the interactions with SCs. These materials are often constructed into porous, 
fibrous hydrogel scaffolds. A porous structure can provide the structural void into which 
cells can migrate, whereas a fibrous scaffold mimics the structure of the ECM. Hydrogels, 
which are water-swollen polymers, may be fabricated from natural ECM components or 
from synthetic materials to mimic the microenvironment. Vasculogenesis from hESCs has 
been demonstrated in alginate, dextran, and hyaluronic acid hydrogels [73-75], while ECs 
derived from hESCs have generated functional vascular networks within a synthetic porous 
scaffold [76]. One study has demonstrated that EPCs are able to form tube-like structures; 
it compared the formation and functions of tissue-engineered blood vessels generated by 
peripheral-blood- and umbilical-cord-blood-derived EPCs in a model of in vivo 
vasculogenesis. The study found that adult peripheral blood EPCs formed blood vessels 
that were unstable and that regressed within three weeks. In contrast, umbilical cord blood 




1.3.2 Delivery of angiogenic factors.  
One intrinsic method for enhancing neovascularization of an engineered scaffold 
utilizes biochemical signaling pathways. Studies have shown that to improve the ability of 
host vessels to infiltrate the scaffold and damaged tissues, many growth factors such as 
vascular endothelial growth factor (VEGF), platelet-derived growth factor, transforming 
growth factor-beta, and basic fibroblast growth factor promote angiogenesis and 
vasculogenesis in either cell culture or animal models[78]. Incorporating angiogenic 
factors into scaffolds has proven to have positive effects on vascularization. For example, 
VEGF is one of the most extensively studied and crucial angiogenic factors. Upon 
implantation of a VEGF-hyaluronic acid hydrogel into mice to study its in vivo effects, 
researchers observed an increase in microvessel density and growth, demonstrating that 
ECs are able to migrate through the hydrogel and that the VEGF contributed a strong 
angiogenic effect [79]. EPCs from umbilical cord blood, cultured on a VEGF-fibrin 
hydrogel, were observed to maturate and differentiate towards ECs [80], while collagen 
gel modified with VEGF has been shown to enhance capillary formation and tissue in 
growth [81].  
Overall, a great deal of effort has been expended to develop scaffolds which mimic 
the natural environment in which stem cell populations reside. However, additional work 
is required in order to obtain clinically successful implants. Therefore, the future of TE and 
RM requires focusing on design techniques that improve stem cell retention, survival, 
proliferation, and differentiation. This endeavor will involve many interdisciplinary fields, 
including medicine, biology, engineering and material science. In addition, such factors as 




designing a biomimetic scaffold. Continued improvements in biomaterial design and 
greater understanding of stem cell biology hold the promise of allowing the successful 
treatment of many diseases.  To reach this goal, TE and RM must cooperate to create 
functional biological substitutes which repair, improve, and maintain the original tissue 
function. 
 
1.4 Thesis Overview 
Tissue engineering and regenerative medicine have been playing a pivotal role 
in recent biomedical field advancement. Combining improved biomaterials designs 
and stem cell technology enable researchers testing novel approaches for their clinical 
relevance. The overall hypothesis of this thesis is that synthetic bioactive hydrogel can 
be exploited for translational approach to study vascular disease and to elicit 
translational angiogenesis therapy to treat injuries. This thesis can be divided into three 
specific aims: 
Specific Aim 1: Using in vitro 3D bioactive hydrogel to study cancer angiogenesis. 
There is a growing trend for in vitro platforms to model basic biological sequences 
in disease model, here we utilized 3D hydrogel scaffold to resemble the 
microenvironmental effects on cancer cell fate and its angiogenic potential. The study for 
this specific aim will be presented in Chapter  3. 
Specific Aim 2: Investigate in vivo diabetic disease model for therapeutic wound 
healing. 
For regenerative medicine purpose, we further expand the vascularized bioactive 




injury model to investigate potential therapeutic strategy.  The study for this specific aim 
will be presented in Chapter 4. 
Specific Aim 3: Utilizing bioactive hydrogel scaffold to treat in vivo porcine burn 
injury. 
Severe deep tissue injuries also pose opportunities for new therapeutic strategy. 
Here we utilize our bioactive hydrogel platforms to investigate the burn wound healing in 
larger animal as an approach for future regenerated medicine application in human. The 
study for this specific aim will be presented in Chapter 5. 








2 Overview of Experimental Methods 
 
2.1  Macromer synthesis  
Acrylated HA macromer synthesis was conducted as previously reported [82-84]. 
In brief, AHA was synthesized in two steps: (1) the tetrabutyl-ammonium salt of HA (HA-
TBA) was formed by reacting sodium hyaluronate (90 kDa, LifeCore Biomedical) with the 
ion exchange resin Dowex-100 (Sigma) and neutralizing with 0.2M TBA-OF (Sigma); (2) 
acrylic acid (3 eq) and HA-TBA (1 eq) were coupled in the presence of 
dimethylaminopyridine (DMAP; 0.15 eq) and di-tert-butyl dicarbonate (3 eq) in DMSO, 
followed by dialysis and lyophilization. 1H NMR spectra were used to confirm the 
modification of the AHA. The cell-adhesive peptide GCGYGRGDSPG (RGDS, molecular 
weight [MW]: 1025.1 Da) and MMP-sensitive peptide crosslinker 
GCRDGPQGWGQDRCG (MMP, MW: 1754 Da) were purchased (Genscript, > 95% 
purity per manufacturer HPLC analysis.) 
The dextran hydrogel macromere was synthesized and characterized as previously 
[85-87]. Briefly, allyl isocyanate (AI) was incorporated into dextran by dissolving pre-
dried dextran (e.g. 2g) in anhydrous DMSO (20mL) at room temperature under nitrogen 
gas. Reaction catalyst DBTDL was added (0.210mL), and AI (0.240 mL) was added to the 
solution dropwise. After the reaction, the solution was precipitated in cold excess 
isopropanol and filtered. Next the remaining hydroxyl groups in Dex-AI were substituted 




DMSO (30ml) under nitrogen gas. Meanwhile, BEAHB (3.75g) was dissolved in DMSO 
(10ml) in a separate chamber. Catalyst TEA (11.2mL) was added to the Dex-AI DMSO 
solution, and the dissolved BEAHB in DMSO was added to the solution dropwise. After 
the reaction, TEA salt was filtered and the resulting solution was precipitated in cold excess 
isopropanol and filtered. The resulting Dex-AE was then dialysized against distilled water 
for 3 days and lyophilized for additional 3 days. The purified polymer was stored in vacuum 
until further use. For characterization NMR of the polymer for degree of substitution for 
thiol group (AI) and aminated group (AE) was performed. For crosslinking, 
polyethylglycol diacrylate (PEGDA) was synthesized as previously established and 
dialysized against distilled water for 3 days and lyophilized for additional 3 days. The 
purified polymer was stored in 4°C until further use. 
 
 
2.2 Cell cultures 
HT1080 cells (ATCC, Manassas, Virginia) were cultured according to the 
manufacturer’s instructions in Dulbecco’s Modified Eagle’s medium (DMEM, GIBCO) 
supplemented with 10 % fetal bovine serum (FBS GIBCO). For cell encapsulation and cell 
cycle studies, HT1080 cells were synchronized under serum-free media for three days with 
daily media change. Human umbilical cord blood ECFCs were provided by Dr. Merv C. 
Yoder, Indiana University School of Medicine, and expanded and used for experiments 
between passages 6 and 9, as previously described [82, 88]. ECFCs were cultured in flasks 
precoated with type I collagen (Roche Diagnostics, Basel, Switzerland), in endothelial 




VEGF165 (Pierce, Rockford, IL). All cell cultures were incubated in a humidified incubator 
at 37 °C in an atmosphere containing 5 % CO2. Both HT1080 cells and ECFCs were 
passaged every four to five days with 0.05 % trypsin (Invitrogen, Carlsbad, CA), and media 
were changed every other day. 
Early vascular cells (EVCs) expansion and differentiation from BC1 and type 1 
diabetes (T1D) human induced pluripotent stem cell (hiPSC) lines were followed our 
establsihed protocols [89, 90]. Briefly, undifferentiated hiPSC (BC1 and T1D) were 
maintained on inactived mouse embryonic fibroblast feeder layers in growth medium with 
80 percent ES-EMEM/F12 (Global Stem), 20 percent serum replacement (Invitrogen), and 
10ng/ml basic fibroblast growth factor (bFGF). For differentiation, hiPSCs were collected 
through digestion with EDTA (Promega), single cells were seeded and plated onto collagen 
IV (Trevigen)-coated with concentration of 5 X 104 cell/cm
2 supplemented with 10µM 
ROCK inhibitor Y-27632 (Stemcell Technologies). Cells were cultured for 6 days in a 
differentiation medium composed of alpha-MEM (Invitrogen), 10% FBS (HyClone), and 
0.1 mM β-mercaptoethanol (β-ME), with the medium changed daily. Differentiated cells 
were collected through digestion with TrypLE (Invitrogen) on day 6 and seeded at a 
concentration of 2 X 104 cells/cm2 on collagen type IV-coated plates in endothelial cell 
growth media (ECGM) (PromoCell) supplemented with 2% FBS, 50 ng/mL VEGF with 
10 μM SB431542 (Tocris) for 6 d. The medium was changed every other day. ECFC 
(Lonza) were cultured under manufactured protocols. Briefly, cells were seeded and 
expanded in endothelial growth media EGM-2 (Lonza) and cells with passages 6 through 





2.3  In vitro cellular scaffolds 
2.3.1 Hydrogel formation 
For hydrogel formation, AHA macromer was dissolved in triethanolamine-buffered 
saline (TEOA buffer: 0.2 M TEOA) at 3 % w/w. The cell adhesive peptides (RGDS, 
GenScript) were dissolved in TEOA buffer and added to the AHA solution to reach a final 
peptide concentration of 3.8 mM and allowed to react for one hour with gentle shaking. 
For crosslinking, MMP crosslinker (MMP, GenScript) dissolved in TEOA buffer was 
added to reach a final concentration of 2.57 mM (soft) 5.15 mM (medium), or 10.3mM 
(stiff). Hydrogels were allowed to swell for three hours prior to mechanical testing.  
For hydrogel preparation Dex-AE and PEGDA were dissolved at the weight ratio of 
80:20 into phosphate-buffered saline containing 0.1% (w/w) Irgacure® 2959. The mixture 
was pipetted into a sterile mold made by polydimethylsiloxane and photocrosslinked 
(10mW/cm2 of UV light for 10 minutes). Hydrogels were swelled against PBS for swelling 
ratio and crosslink density characterization. In vitro cell toxicity was carried using WST 
assay (Sigma) as well as pilot in vivo burn mice tests [87] were done to confirm AE 
hydrogel therapeutic properties.  
 
 
2.3.2 Cell encapsulation 
We engineered human vascular networks within the AHA hydrogels similar to our 
previous studies [82, 91]. AHA macromer was dissolved in triethanolamine buffered saline 
(TEOA buffer: 0.2M TEOA) at 3 wt%. Cell adhesive peptides (RGDS, GenScript) were 




of 4.8mM along with Recombinant human VEGF165 (Pierce), bFGF (Invitrogen), Ang-1 
(R&D Systems), TNF-alpha (R&D Systems), and stromal cell-derived factor-1 (SDF-1; 
R&D Systems) were also added into the AHA-RGDs mixture at 50 ng/ml. The mixture 
was allowed to react for 1 hour with gentle shaking.  For crosslinking, MMP cross linker 
(MMP, GenScript) dissolved in TEOA buffer was added to a final concentration of 5.15 
mM. Preconditioned ECFCs and EVCs were encapsulated in AHA hydrogels at a density 
of 5 X 106 cells/ml by suspending the cells in the AHA-RGD solution as described above 
prior to the addition of the MMP crosslinker. A 50ul volume of the final mixture was 
pipette into sterile molds (5 mm diameter, 2 mm height) and allowed to react for 10 minutes 
at room temperature in laminar flow hood.  
Preconditioned HT1080 cells were encapsulated in AHA hydrogels with densities 
of 1, 5, and 10 x 106 cells/ml by suspending the cells in HA-RGD solution, prior to addition 
of the MMP crosslinker. We pipetted 50 µl of the final mixture into sterile molds and 
allowed it to react for ten minutes at room temperature in a laminar flow hood. The 
constructs were then cultured in HT1080 growth media in the conditions described 
throughout this paper. 
 
2.4 Animal use 
2.4.1 Rodent 
The standard protocol for STZ induced diabetes mellitus provided by Animal 
Models of Diabetic Complications Consortium was followed [92-94]. Nude mice at about 
2-2.5 months of age (about 20-25 g body weight) were randomly assigned to a diabetic or 




injection of STZ at a dose of 50 mg/kg body weight (STZ is freshly dissolved in citrate 
buffer, pH 4.5). Prior to injection, mice were fasted for 4 to 6 hours. The weight and blood 
glucose of each mouse were checked daily for up to 2 weeks after the STZ injection. 
Successful STZ-induced diabetic mellitus nude mice were confirmed by two consecutive 
blood glucose levels readings which were higher than 300 mg/dl over a 48 hour period. 
Blood glucose was measured using an Accuchek blood glucose meter (Roche) by obtaining 
20-25μl of blood from the tail vein puncture (30 gauge needle). 
DFU animal model was constructed by incorporating varies protocols from the 
literatures [92, 95-98]. After diabetic mellitus was confirmed, diabetic induced nude mice 
were anesthetized with isoflurane (Thermo Fisher). A depilatory was applied (Nair), prior 
to wound creation, to ensure better dressing adherence. Next, 2 x 6mm diameter punch 
wounds were made, using a biopsy punch (Integra), taking care to remove full-thickness 
skin on each side of the posterior dorsum. Vascularized constructs, which were generated 
in vitro, were then transplanted into one side of the animal (one per wound). The time point 
was logged as day 0 post-wounding. Betadine was applied around the periphery of the 
wound to enhance dressing adherence. The other wound on the other side is left no 
vascularized constructs treatment. Both wounds were then covered with Tegaderm 
dressing (3M). 6 to 8 constructs were implanted for each group at each time point. At each 
time point of interests, as described below, human specific fluorescein- conjugated Ulex 
europaeus I (UEA-I) Lectin (1:10; Vector Laborato) and mouse-specific rhodamine-
conjugated Isolectin Griffonia simplicifolia (GS)-IB4 (1:10; Invitrogen) were injected 
through the tail veins of the mice [82, 89, 91]. After 30 minutes, the mice were euthanized, 




processed for immunohistochemistry or histology. The Johns Hopkins University 
Institutional Animal Care and Use Committee approved all animal protocols.  
2.4.2 Procine 
Surgical procedures were approved by the Institutional Animal Care and Use 
Committee at Thomas D. Morris, Inc. prior to the experiments. All pigs were fasted for at 
least 12 hours prior to any surgical procedure. Anasthesia was induced by an intramuscular 
injection of Telazol cocktail reconstituted with ketamine and xylazine. Then, the pig was 
endotracheally intubated and ventilated mechanically to aid breathing and to provide up to 
1.5% of isoflurane (depending on the painfulness of the procedure) to maintain anasthesia. 
In addition, blood pressure, heart rate, body temperature, and blood oxygen level was 
monitored. Bair Hugger® was placed under the pig and set to 43°C to maintain a normal 
body temperature.  
Circular biopsy punches were used for partial or complete excision for full-
thickness wound down to the necrotic adipose layer. Wounds were at least 3cm apart from 
one another to minimize hindered wound healing process due to proximity. After the 
excision procedure, wounds were cleaned with sterile gauze to temporarily stop bleeding. 
Half of the wounds were treated with dextran hydrogel and the other half were left 
untreated. Hydrogels were crosslinked in molds that matched the size of the excised 
wounds. Treated and untreated wounds were first sealed with Tegaderm® (3M). The 
peripheries of the wound site was applied with compound benzoin tincture (Medical 
Chemical, Corp) to enhance the Tegaderm® adherence to the skin. An additional layer of 
Vetrap® (3M) was applied to the torso and elastic body suit (VetMedCare) were worn over 




forming epidermis from traumatization during bandage change, a non-adhesive Curity® 
dressing (Covidian) was placed under the Tegaderm®. After wound closure, only an elastic 
body suit was worn over the wounds. For retreatment, re-debridement was made and a new 
half the thickness hydrogel was placed on top for retreatment. Secondary excision was 
made on control group as well for the retreatment group. Dressings were changed three 
times a week until wound closure was complete. Before the dress change, the pig was put 
under anesthesia with an intramuscular injection of Telazol cocktail reconstituted with 
ketamine and xylazine. The pig did not receive isoflurane because the procedure was quick. 
Before reapplying dressings, the wound area was scrubbed with 4% chlorhexidine and 
ethanol. The area was wiped with dry gauze and new dressings were applied.  
 To evaluate healing, skin specimens were biopsied at each time point as complete 
horizontal cross-sections of approximately 5cm in thickness with a sterile blade. 
Analgesics were administered before wound creating and biopsy procedures, and 
transdermal fentanyl patch was applied for 9 days post-operation.  Blood tests were 
performed regularly to monitor the pig’s health throughout the study. 
 
2.5 Healing analysis 
2.5.1 Bloodflow and Planetary Measurement 
During the study, the blood flow profiles inside the wounds were monitored 
noninvasively using moorFLPI speckle contrast imager (Moor Instruments, Inc.). The 
measurements were normalized by the blood flow measurements of the adjacent healthy 
skin area. Wound gap area was measure photometrically by tracing the opened wound edge 






Following fixation of the explants, the samples were dehydrated in serial ethanol 
(70%–100%), embedded in paraffin, serially sectioned at 5 µm, and stained with either 
H&E, Masson  trichrome, and Verhoeff-van Gieson's stain or immunohistochemistry for 
CD31 (1:50 Abcam), cytokeratin 14 (1:50 Abcam), MAC387 (1:50 Abcam), SMA (1:100 
Dako), Dapi (1:1000), PGP9.5 (1:500 AbD Serotec) and matching Alexaflour secondary 
(1:500 Lifetech) or immunoperoxidase stains for anti-mouse alpha-smooth muscle actin 
(alpha-SMA) (Abcam), or anti-human CD31 (Dako). Double staining was performed using 
the same anti-human CD31 and anti-mouse alpha-SMA followed by conjugation with anti-
mouse Alexa Fluor 488 (Life Technologies) or anti-rabbit Alexa Fluor 564 (Life 
Technologies) and counter stain with Dapi. Histological images were taken with an upright 
light microscope (Nikon Accuscope 3000) and a camera (Nikon DS-F12). Full specimens 
images were scanned and tiled together using automated motor controlled Nikon T1 and 
tiled together with corresponded software (Nikon Nis-Element). Fluorescent images were 
taken with confocal (Zeiss LSM780).   The area and number of vessels inside the wounds 
were quantified using ImageJ software (National Institutes of Health) with histology 
sample of each wound stained with CD31. The vessels were imaged at the edges, middle, 
and top portions of each wound, and the positively stained areas were selected using the 
software’s threshold function. The selected areas were then quantified using “Analyze 
Particles” plugin of ImageJ. “Microvessels” with areas less than 78μm2 were excluded to 
filter out noise.  




rete ridge formation density as previously described [99]. Collagen fiber deposition was 
quantified from Masson trichrome images by calculating the percentage of collagen fiber 
presented in the wound. Briefly, using ImageJ, we quantified the percentage of stained 
collagen fibers in the given area in each group. Elastin fibers were quantified from 
Verhoeff-van Gieson's stain across the dermis area adjacent to the epidermis similarly to 
the collagen. Nerve innervation analysis was performed on a 25µm paraffin sections on 
gelatin coated slides. Samples were incubated in primary antibody overnight and 1 hour in 
secondary antibody. Slides were then analyzed in confocal using serial z-stack imaging. 
Final images were maximum intensity projected through z axis for the final images.  
 
 
2.6 Gene Expression 
Two-step RT-PCR was performed for VEGF, ANG-1, MMP-1, GLUT-1, BNIP3, 
BNIP3L, 18S, GAPDH, and beta-actin, and samples were examined in triplicate, analyzed, 
and graphed. Briefly, RNA was extracted using TRIzol (GIBCO) according to the 
manufacturer’s instructions. To extract porcine RNA, a small specimen was collected from 
each wound at different time points and snap-frozen in liquid nitrogen. The specimen was 
crushed with pestle and mortar, and the powdered sample was put in 1mL of Trizol reagent 
and stored in -80°C until further use. Total RNA was quantified by nanodrop 
spectrophotometer. Gene expression assays were performed on an Applied Biosystems 
StepOne Real-Time PCR system according to the manufacturer’s instructions. The relative 
expression of genes was normalized to the indigenous control genes. The comparative CT 




experiments (n=3) were averaged and graphed. Wound healing and ECM RT-PCR array 
sets (Qiagen) were used to compare the expression profile inside the treated and non-treated 
wounds at different time points. For each primer, the comparative computerized method 
provided by the manufacturer was used to calculate the amplification differences between 



































3 Hylauronic acid hydrogel stiffness and 
oxygen tension affect cancer cell fate and 
endothelial sprouting 
 
Three-dimensional (3D) tissue culture models may recapitulate aspects of the 
tumorigenic microenvironment in vivo, enabling the study of cancer progression in vitro. 
Both hypoxia and matrix stiffness are known to regulate tumor growth. Using a modular 
culture system employing an acrylated hyaluronic acid (AHA) hydrogel, three hydrogel 
matrices with distinctive degrees of viscoelasticity — soft (78±16 Pa), medium (309± 57 
Pa), and stiff (596± 73 Pa) — were generated using the same concentration of adhesion 
ligands. Oxygen levels within the hydrogel in atmospheric (21 %), hypoxic (5 %), and 
severely hypoxic (1 %) conditions were assessed with a mathematical model. HT1080 
fibrosarcoma cells, encapsulated within the AHA hydrogels in high densities, generated 
nonuniform oxygen distributions, while lower cell densities resulted in more uniform 
oxygen distributions in the atmospheric and hypoxic environments. When we examined 
how varying viscoelasticity in atmospheric and hypoxic environments affects cell cycles 
and the expression of BNIP3 and BNIP3L (autophagy and apoptosis genes), and GLUT-1 
(a glucose transport gene), we observed that HT1080 cells in 3D hydrogel adapted better 
to hypoxic conditions than those in a Petri dish, with no obvious correlation to matrix 




alternating metabolism mechanisms. Further, we examined how HT1080 cells cultured in 
varying viscoelasticity and oxygen tension conditions affected endothelial sprouting and 
invasion. We observed that increased matrix stiffness reduced endothelial sprouting and 
invasion in atmospheric conditions; however, we observed increased endothelial sprouting 
and invasion under hypoxia at all levels of matrix stiffness with the upregulation of 
vascular endothelial growth factor (VEGF) and angiopoeitin-1 (ANG-1). Overall, HT1080 
cells encapsulated in the AHA hydrogels under hypoxic stress recovered better from 
apoptosis and demonstrated greater angiogenic induction. Thus, we propose that oxygen 
tension more profoundly influences cell fate and the angiogenic potential of 3D cultured 




Three-dimensional (3D) cell culture models recapitulate aspects of the in vivo 
extracellular matrix (ECM) microenvironment, allowing the study of tumor development 
and progression under pathologically relevant culture conditions [100-104]. Specifically, 
hydrogels are structurally and mechanically similar to the native ECM of many tissues and 
have been utilized as matrices to study cellular responses to a range of microenvironmental 
signals [105-107]. Hydrogels composed of natural matrices have inherently limited 
tunability for independently studying effects of several physiochemical properties on 





In contrast, engineered hydrogels that mimic various cues of the tumor 
microenvironment and ECM-cell interactions can be used to study the independent and 
codependent effects of specific cues in the microenvironment on cancer cell responses 
[104, 108]. For example, highly porous scaffolds fabricated from synthetic poly(lactide-
co-glycolide) have been used to generate an in vitro human tumor model that exhibits 
microenvironmental conditions representative of tumors in vivo [109]. More recently, Gill 
et al. utilized a synthetic polymer-based scaffold composed primarily of polyethylene 
glycol, which offers biospecific cell adhesion and cell-mediated proteolytic degradation 
with independently adjustable matrix stiffness. They demonstrated that altering both matrix 
stiffness and the concentration of cell-adhesive ligand significantly influenced epithelial 
morphogenesis of a metastatic cell line (344SQ) [110]. ECM rigidity has been show to alter 
tumor cell proliferation and migration [111, 112] and resistance to chemotherapeutics 
[112]. Similarly, ECs have been found to change their behavior and morphology depending 
on substrate stiffness [113, 114]. Hence, engineering the mechanical stiffness of hydrogel, 
while decoupling it from other key properties such as cell adhesion, may elucidate how the 
tumor’s physical environment contributes to its growth and angiogenesis. 
Along with the adhesive and mechanical properties of the microenvironment, 
hypoxia is an important determinant of cell behavior. Hypoxia occurs when the partial 
pressure of O2 falls below 5 %, inducing myriad cellular and systemic adaptations [115, 
116]. In fact, during tumor growth, cells inevitably experience depletion of nutrients, 
including oxygen due to extensive growth [117]. Cellular responses to hypoxia are 
primarily regulated by hypoxia-inducible factors that accumulate under hypoxic conditions 




such as promoting tumor growth and angiogenesis during embryonic development [117, 
123, 124].  
 
3.2 Materials and Methods 
3.2.1 Cell cultures 
 HT1080 cells (ATCC, Manassas, Virginia) were cultured according to the 
manufacturer’s instructions in Dulbecco’s Modified Eagle’s medium (DMEM, GIBCO) 
supplemented with 10 % fetal bovine serum (FBS GIBCO). For cell encapsulation and cell 
cycle studies, HT1080 cells were synchronized under serum-free media for three days with 
daily media change. Human umbilical cord blood ECFCs were provided by Dr. Merv C. 
Yoder, Indiana University School of Medicine, and expanded and used for experiments 
between passages 6 and 9, as previously described [82, 88]. ECFCs were cultured in flasks 
precoated with type I collagen (Roche Diagnostics, Basel, Switzerland), in endothelial 
growth medium (EGM, PromoCell, Heidelberg, Germany) supplemented with 1 ng/ml 
VEGF165 (Pierce, Rockford, IL). All cell cultures were incubated in a humidified incubator 
at 37 °C in an atmosphere containing 5 % CO2. Both HT1080 cells and ECFCs were 
passaged every four to five days with 0.05 % trypsin (Invitrogen, Carlsbad, CA), and media 
were changed every other day. 
3.2.2 Macromer synthesis 
 AHA macromer synthesis was performed as reported previously [125]. Briefly, we 
synthesized AHA in two steps: (1) the tetrabutyl-ammonium salt of HA (HA-TBA) was 
formed by reacting sodium hyaluronate (90 kDa; LifeCore Biomedical, Chaska, MN) with 




(2) acrylic acid (3 [eq]) and HA-TBA (1 eq) were coupled in the presence of 
dimethylaminopyridine (DMAP; 0.15 eq) and di-tert-butyl dicarbonate (3 eq) in DMSO, 
followed by dialysis and lyophilization. We used 1H NMR spectra to confirm the 
modification of the AHA. The cell-adhesive peptide GCGYGRGDSPG (RGDS, molecular 
weight [MW]: 1025.1 Da) and MMP-sensitive peptide crosslinker 
GCRDGPQGWGQDRCG (MMP, MW: 1754 Da) were purchased (Genscript; greater than 
95 % purity, per manufacturer’s HPLC analysis). 
 
3.2.3 In vitro cellular scaffolds 
3.2.3.1 Hydrogel formation 
For hydrogel formation, AHA macromer was dissolved in triethanolamine-buffered 
saline (TEOA buffer: 0.2 M TEOA) at 3 % w/w. The cell adhesive peptides (RGDS, 
GenScript) were dissolved in TEOA buffer and added to the AHA solution to reach a final 
peptide concentration of 3.8 mM and allowed to react for one hour with gentle shaking. 
For crosslinking, MMP crosslinker (MMP, GenScript) dissolved in TEOA buffer was 
added to reach a final concentration of 2.57 mM (soft) 5.15 mM (medium), or 10.3mM 
(stiff). Hydrogels were allowed to swell for three hours prior to mechanical testing. The 
elastic modulus (G’) was measured using a constant strain rheometer with steel cone plate 
geometry (25 mm in diameter; RFS3; TA Instruments). The strain was maintained at 20 % 
during the time sweeps by adjusting the stress amplitude at a frequency of 10 Hz. Three 
samples were tested for each gel. The tests occurred in a humidified chamber at a constant 
temperature (25 °C) at 30-second intervals. We then calculated Young’s elastic modulus 




approach 0.5, and the relationship becomes E=3G’. The same approach was used to 
measure the constructs along the culture period. 
3.2.3.2 Cell encapsulation 
Preconditioned HT1080 cells were encapsulated in HA hydrogels with densities of 
1, 5, and 10 x 106 cells/ml by suspending the cells in HA-RGD solution, as above, prior to 
addition of the MMP crosslinker. We pipetted 50 µl of the final mixture into sterile molds 
and allowed it to react for ten minutes at room temperature in a laminar flow hood. The 
constructs were then cultured in HT1080 growth media in the conditions described 
throughout this paper.  
 
3.2.4 In vitro hypoxia construct 
3.2.4.1 Oxygen modeling 
Oxygen tension profiles were modeled within the gels following a previously 
established method for collagen gels [126]. Briefly, to estimate DO gradients in 3D AHA 
gels, we first determined the Vmax and Km parameters of HT1080 cells in 3D AHA 3 % w/w 
gel. We attached oxygen sensor patches (Presens, Regensburg, Germany) to the bottoms 
of the 96-well plates. Cells were then seeded at 2 million cells/ml with 50 µl of media in 
the well. Next, we sealed the well completely, to provide a closed system for oxygen 
measurement, and allowed them to reach anoxia. Using DO level data measured 
continuously, we estimated Vmax and Km using the RSS method to find the best fit between 




for the given conditions to estimate the DO gradients throughout the gel depth, using the 
commercial software package Comsol Multiphysics (Comsol, Los Angeles, CA). 
3.2.4.2 Hypoxia experiments 
 AHA constructs were modeled within culture media, allowing oxygen permeability 
in all directions. Hypoxia (5 % O2) experiments were conducted as described previously 
[127]. Briefly, cells were cultured in a hermetically sealed, humidified modular incubator 
chamber (Billups-Rothenberg, Del Mar, CA, USA), which was flushed with an appropriate 
gas mixture (a 5 % O2/5 % CO2/N2 balance) three times every 30 minutes at the beginning 
of each experiment. Placing a plastic Petri dish containing 10 ml of sterile water on the 
chamber bottom maintained humidity during experiments.  
 
3.2.5 Flow cytometry and cell cycle analysis 
 Flow cytometry was performed for cell cycle analysis and proliferation. Briefly, 
encapsulated HT1080 cells were exposed to hypoxia at 5 % O2 tension for up to three days. 
Gels were harvested at desired time points and digested with hyaluronidase (Sigma) for ten 
minutes and then 0.25 % trypsin for five minutes to dissociate the cell from the hydrogel. 
The samples were then centrifuged to separate gels and cells. Next, we fixed the cell pellets 
in ice-cold 70 % ethanol overnight at 4 °C. Triton X-100 (0.1 %) and RNase A (100 μg/ml; 
Qiagen, Valencia, CA) were added to obtain a final concentration of 106 cells/ml, and cells 
were incubated in the solution for two hours at 37 °C before being stained with 50 μg/ml 
propidium iodide (Sigma Aldrich, St. Louis, MO) for 15 minutes at 37 °C. For 




with anti-human Ki67 (Life Technology) for 30 minutes, and washed with PBS. To avoid 
clumping, we strained the cells through a 40 μm cell strainer. Cell cycles were analyzed 
with the BD FACSCalibur flow cytometer (Becton Dickinson, NJ), reading the signals 
detected by FL2. Data were analyzed using FlowJo software, version 7.5, to determine the 
frequencies of each cell cycle phase.   
 
3.2.6 Real-time quantitative RT-PCR 
 Two-step RT-PCR was performed for VEGF, ANG-1, MMP-1, GLUT-1, BNIP3, 
BNIP3L, 18S, GAPDH, and beta-actin, and samples were examined in triplicate, analyzed, 
and graphed. Briefly, RNA was extracted using TRIzol (GIBCO) according to the 
manufacturer’s instructions. Total RNA was quantified by nanodrop spectrophotometer. 
Gene expression assays were performed on an Applied Biosystems StepOne Real-Time 
PCR system according to the manufacturer’s instructions. The relative expression of genes 
was normalized to the indigenous control genes. The comparative CT method was used to 
calculate amplification differences on targeted genes. The values for experiments (n=3) 
were averaged and graphed. 
 
3.2.7 2D sprouting assay  
2D sprouting assays to assess the sprouting potential were based on previously 
established methods using collagen or fibrin gels [88, 128]. AHA hydrogels were prepared 
as described above, with or without the encapsulation of HT1080 cells or with the addition 




(SDF-1, R&D Systems) at a concentration of 125 μM. ECFCs were seeded on top of the 
AHA hydrogels and cultured for an additional 24 hours to allow invasion into the gels. 
Samples were then fixed and processed for fluorescence staining and further image analysis 
(see below). 
 
3.2.8 Fluorescence staining 
 Following sprouting assay, ECFC-HT1080 constructs were fixed using formalin 
for 30 minutes and washed with PBS. For staining, the constructs were permeabilized with 
a solution of 0.1 % Triton-X for 15 minutes, washed with PBS, stained with fluorescein-
conjugated UEA-I lectin for two hours, rinsed, and then stained with DAPI for 15 minutes. 
The labeled samples were examined using a side view perpendicular to the sprouting 
direction by either fluorescence microscopy (Olympus BX60; Olympus, Center Valley, 
PA) or confocal microscopy (LSM 510 Meta; Carl Zeiss). To analyze the sprouting length 
of ECFCs, measurement tools in Image J (NIH) were used and normalized to the medium 
gel without encapsulated cancer cells under atmospheric conditions while keeping all other 
formulations the same; this served as a positive control and reference point across different 
sets of experiments. 
 
 
3.2.9 Graphs and statistics 
 All experiments and assays were performed on at least triplicate samples with 




were determined using unpaired two-tailed t-tests or two-way ANOVA where appropriate 
(GraphPad Prism 4.02). Significance levels were determined using post-tests with *P<.05, 
**P<.01 and ***P<.001. 
 
 
3.3 Results and Discussion 
3.3.1 Hyaluronic hydrogel viscoelasticity during culture 
Hyaluronic acid (HA), a glycosaminoglycan abundantly present in the ECM, holds 
potential as an important component of matrices for the study of cancers and angiogenic 
responses, since it may facilitate cancer progression, invasion, migration, and angiogenesis 
[129]. Previously, we engineered a modular culture system using an acrylated HA (AHA) 
hydrogel to generate a functional human microvascular network [82] and to induce 
endothelial cell (EC) sprouting and angiogenesis [88]. This same AHA hydrogel system 
may be useful for studying how hypoxia and stiffness cues in the tumor microenvironment 
affect cancer cell fate (Figure 3-1A). The AHA macromers contain acrylate groups that 
react with thiols in a Michael-type addition reaction, such that crosslinking can occur with 
a dithiol and chemical modification can occur with a monothiol. Specifically, we 
crosslinked AHA with an enzymatically degradable peptide (with a sequence susceptible 
to matrix metalloproteinases [MMPs] -1 and -2) that contained two cysteines and 
incorporated adhesion through a peptide (i.e., RGD) that contained one cysteine, where the 
cysteines provided thiol groups to react with acrylates. This system enables us to alter the 
hydrogel’s crosslinking density by changing the amount of MMP crosslinker added while 




approach, we generated three hydrogel matrices with distinctive levels of viscoelasticity: 
soft (78±16Pa); medium (309± 57Pa) and stiff (596± 73Pa; Figure 3-1C).  
We first examined cancer cell encapsulation in the AHA hydrogels with defined 
viscoelasticity. For our studies, we chose a fibrosarcoma-derived cell line, HT1080, which 
tends to be highly angiogenic, mobile, and metastatic, making it a good candidate for the 
soft tissue viscoelasticity range [130-132]. We noticed that, after 24 hours of encapsulation, 
HT1080 cells in both medium and stiff hydrogels began to spread, but they started to form 
aggregates in the softest hydrogels (data not shown). Within 72 hours, most of the HT1080 
cells encapsulated in stiff and medium hydrogels had spread, while most of those in the 
soft hydrogels aggregated into clumps and spread only occasionally (Figure 3-2A). 
Examining the viscoelasticity, we first noticed that after cell encapsulation, the stiffness of 
the hydrogels slightly altered to soft (66±13Pa); medium (361± 65Pa) and stiff (485± 63Pa) 
constructs; we also found that all constructs types, but not hydrogels alone, became softer 
along the culture period, reaching 14±10Pa; 77±49Pa; and 96±71Pa in the soft, medium, 
and stiff hydrogels, respectively. (Figure 3-2B). Indeed, due to the cell clusters, constructs 
made of soft gels became unstable and difficult to maintain, with many clusters falling off 
the AHA hydrogels. Thus, the studies were limited to the first three days of encapsulation 







Figure 3-1. Acrylated HA hydrogels. 
(A) Schematic representation of AHA hydrogels, which are formed by reacting AHA 
macromers with RGD-containing peptides and MMP-sensitive crosslinkers, where the 
crosslinker concentration controls viscoelasticity. (B) Rheology frequency sweeps of 
AHA hydrogel with varying MMP crosslinker concentrations, showing that the 
modulus depends on crosslinker concentration. (C) Elastic modulus following 






3.3.2 Oxygen tension gradient in hydrogel scaffold 
We next determined the oxygen tension and gradients throughout the hydrogel 
matrices. Our previous studies showed that dissolved oxygen (DO) levels decrease during 
2D culture of various human cell types [133] and that these decreases become even more 
dramatic in 3D hydrogel cultures, which require higher cell-seeding concentrations [126]. 
Indeed, in a 3D hydrogel culture system, the availability of DO to the cells depends on both 
oxygen diffusion from the air to the culture media and the oxygen consumption of the 
encapsulated cells. The oxygen consumption rate of cells depends on their spatial density 
Figure 3-2. HT1080 cells encapsulated in AHA hydrogels with defined stiffnesses. 
(A) Light microscopy images of three-day culture of HT1080 cells in stiff, medium, 
and soft AHA hydrogels. (B) Viscoelasticity measurements of the different HT1080 





and oxygen uptake rate, which is assumed to follow Michaelis-Menten kinetics. Therefore, 
we first determined the Vmax and Km parameters of HT1080 fibrosarcoma cells. We 
measured DO levels in culture media of HT1080 cells until they reached steady state. We 
plotted the oxygen consumption rate of the HT1080 cells (experimental data) and the 
theoretical Michaelis-Menten equation (numerical model) using the initial Vmax and Km 
values. We then calibrated the graphs while varying the Vmax and Km parameters to obtain 
the best fit to the experimental values according to the residual sum of squares (RSS) 
method (Figure 3-3A). We determined that the Vmax and Km values of HT1080 cells were 
83.19 x 10-18 mol/s and 66 μM, respectively. Mathematical modeling then projected [134, 
135] equilibrium oxygen tension distributions at different boundary conditions (1, 5, and 
21 %) with different cell encapsulation densities (1, 5, and 10 x 106 cells/ml; Figure 3-3B). 
We found that, during the initial culture period, DO gradients were generated throughout 
the thickness of the hydrogel. Specifically, cells at the center regions of the hydrogel 
experienced lower oxygen tensions than either those in the experimental setup (i.e., air gas) 
or those at the edge of the hydrogel. In atmospheric conditions, HT1080 cells encapsulated 
at 10 x 106 cells/ml % experienced around 13 % O2 at the center, compared to 17 % O2 at 
the edge after 30 minutes of gel formation (Figure 3-3C). At 5 % O2, while encapsulation 
densities of 5 x 106 cells/ml or 10 x 106 cells/ml led to oxygen levels below 2 % at the 
center of the hydrogel, at the 1 x 106 cells/ml encapsulation density, cells experienced a 
relatively uniform distribution of 5 % oxygen tension throughout the hydrogel (Figure 
3-3D). At 1 % O2, encapsulation of 5 x 10
6 cells/ml or 10 x 106 cells/ml resulted in anoxic 
conditions at the center of the hydrogel, while encapsulation of 1 x 106 cells/ml yielded 




that using 1 x 106 cells/ml in a 5 % setup would allow us to study the responses of HT1080 
cells to varying stiffnesses in conditions that support uniform DO levels throughout the 
hydrogel. This setting also mimics the initial circulating cancer cell attachment 










Figure 3-3. Predicting DO levels in AHA hydrogels. 
(A) Oxygen consumption rate of HT1080 cells following Michaelis-Menten kinetics. 
Plots were calibrated according to the residual sum of squares method to find the 
best fit between theoretical and experimental values. Vmax and Km values of 
HT1080 cells were 83.19 x 10-18 mol/s and 66 μM, respectively. (B) Schematic of the 
3D HT1080-AHA construct in culture comprises three individual layers: (i) AHA gel 
containing HT1080 cells (middle layer), (ii) growth medium (surrounding layer), 
and (iii) air (top layer). Model prediction of DO levels within the hydrogels at (C) 21 
%, (D) 5 %, and (E) 1 % O2, with HT1080 cells encapsulated at concentrations 
ranging from 1 to 10 x 106 cells/ml during the first hours (left panel: lines show DO 
levels at the center of the hydrogel; broken lines, the DO levels at the edge of the 
hydrogel), and DO gradient profile throughout the hydrogels’ depth after an hour 





3.3.3 Cancer cell fate at various microenvironment parameter 
Many cancer cells are shed into circulation every day. However, very few of them 
survive and become metastatic [137]. Rate-limiting steps at the metastatic site pose 
challenges to circulating cancer cells in their interaction with their microenvironment 
[136], where they can meet several fates (death, dormancy, or survival) modulated by the 
microenvironment. For example, some cancer cells stay quiescent or dormant and only 
later become triggered into a proliferative state for angiogenic purposes [138]. Other tumor 
cells enter the apoptotic/necrotic pathway. To determine the effect of hypoxia on HT1080 
cell fates at different matrix stiffnesses, cells were cultured in serum-free media to 
synchronize their G0 stages before encapsulation. After encapsulation, AHA-HT1080 
constructs were cultured under atmospheric and hypoxic condition for three days. We could 
not observe morphological differences between 3D HT1080 cells cultured under 
atmospheric and hypoxic conditions (data not shown). To examine cell growth, we stained 
the cells with Ki67 proliferation marker. While we detected overall reduced proliferation 
in the 3D AHA hydrogel compared to Petri dish control, we could not detect a significant 
difference in proliferating cells between hypoxic and atmospheric conditions in any of the 
cultures examined (Figure 3-4A). Daily cell cycle analysis further revealed no significant 
differences in population percentage at the S phase or G2 phase (Figure 3-5), suggesting 
that, over the 72 hours, HT1080 cells divide at a similar rate in all conditions examined. 
We noticed that, 24 hours following encapsulation, HT1080 cells experienced apoptosis 
(indicated by the sub-G1 population) and that, under hypoxia, they recover better, resulting 
in significantly lower percentages of apoptotic cells after 48 hours (Figure 3-4B–C). Matrix 




hypoxic conditions, HT1080 cells encapsulated in matrix with medium stiffness 
experienced high levels of apoptotic events compared to cell encapsulated in soft or stiff 
matrices. We therefore examined the upregulation of the autophagy gene of the BCL-2 
family, BCL-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) [139], and the 
proapoptotic gene Bnip3-like protein X (BNIP3L), also of the BCL-2 family, in HT1080 
cells encapsulated in medium AHA hydrogels. While we could not detect differences in 
the expression of BNIP3L (data not shown), upregulation in the expression of BNIP3 was 
detected 24 hours following encapsulation and was downregulated after 48 hours of culture 
(Figure 3-4Di). The same expression pattern could also be detected for glucose transport 
(GLUT-1) in hypoxic HT1080 cells (Figure 3-4Dii). When HT1080 cells were cultured in 
a Petri dish, hypoxia upregulated the expression of GLUT-1 and BNIP3 after 24 hours, 
which further increased after 48 hours, suggesting a rapid response and adaptation to the 
oxygen conditions within the 3D AHA culture microenvironment (Figure 3-4D). These 
results suggest the adaptation of HT1080 cells under hypoxic conditions, rapidly 
recovering from possible autophagy events and alternating metabolism mechanisms. This 
also suggests that HT1080 cells, when cultured in AHA hydrogel under atmospheric 
conditions, experience apoptosis induced by a different mechanism than those examined 
here. Overall, these results suggest that hypoxia and, to a lesser extent, hydrogel stiffness 






Figure 3-4. . HT1080 cell fate in AHA hydrogels with varying stiffnesses in 
atmospheric and hypoxic conditions. 
(A) Proliferation of HT1080 cells encapsulated in stiff hydrogels over the three-day 
experiment in atmospheric and hypoxic conditions. (B) Representative cell cycle flow 
analysis of HT1080 cells encapsulated in stiff hydrogels over the three-day 
experiment in atmospheric and hypoxic conditions. (C) Quantification of the 
percentage of apoptotic cells (sub-G1) in the various conditions. (Di, ii) Quantitative 
RT-PCR for BNIP3 and GLUT-1 expression in HT1080 cells encapsulated in 
hydrogels of medium stiffness (3D) and in Petri dishes (plates) in atmospheric and 







Figure 3-5. Cell cycle. 
Flow analysis of cell cycle phases (G1, S, G2) in HT1080 cells encapsulated in 
hydrogels over the three-day experiment in atmospheric and hypoxic conditions. 
 
3.3.4 Angiogenic potential at different stiffness and oxygen tension. 
Finally, we sought to examine the ability of 3D encapsulated HT1080 cells to 
induce endothelial sprouting under hypoxia at different matrix stiffnesses. Davis and 
colleagues developed an in vitro angiogenesis assay using collagen gels [140, 141]. They 
showed that, in response to sphingosine-1-phosphate (S1P) and stromal cell-derived factor-
1 (SDF-1α), a confluent monolayer of ECs invaded and sprouted into the collagen gels 
underneath in a way that mimicked the appearance of tip cells from preexisting blood 
vessels [141]. We previously adapted this approach and showed that AHA hydrogels could 




role of matrix remodeling during angiogenesis in synthetic biomaterials [142]. In this 
earlier study, we found that endothelial colony-forming cells (ECFCs) cultured on top of 
the medium AHA matrix loaded with SDF1-α and S1P sprouted and invaded the hydrogel 
in atmospheric conditions. These results suggest that, with the necessary adhesion and 
degradation properties, low viscoelasticity, and cytokine stimuli, ECs can sprout and 
invade such AHA hydrogels. In the current study, we modified this approach and 
encapsulated HT1080 cells with SDF-1α and S1P for 24 hours in atmospheric or hypoxic 
conditions, following which we seeded a monolayer of ECFCs and analyzed their sprouting 
and invasion into the AHA hydrogels after a further 24 hours in atmospheric conditions 
(Figure 3-6A). AHA hydrogel encapsulating only SDF-1α and S1P served as controls. It 
should be noted that HT1080 cells encapsulated without the addition of SDF-1α and S1P 
induced little to no EC sprouting and invasion. We observed similar EC sprouting and 
invasion into soft-matrix-encapsulated HT1080 cells in atmospheric and hypoxic 
conditions. While EC sprouting was observed in HT1080 constructs with medium 
viscoelasticity cultured in atmospheric conditions, a significant increase in sprouting length 
was observed in hypoxic conditions. Finally, HT1080 cells encapsulated in stiff hydrogels 
underwent EC sprouting and invasion in hypoxic but not in atmospheric conditions (Figure 
3-6B–C). Overall, we found that, in atmospheric conditions, softer matrices promoted EC 
sprouting and invasion, corresponding to similar cellular events during vasculogenesis [82, 
88, 142-146]. In hypoxia, while the lowest angiogenic response occurred in the stiff matrix, 
soft and medium hydrogels had similarly higher responses. Gene expression analysis of 
HT1080 cells after 24 hours in 3D culture revealed the upregulated expression of MMP-1 




viscoelastic properties of these hydrogels under hypoxic conditions, enabling EC sprouting 
and invasion (Figure 3-7A). Indeed, when we examined HT1080 construct viscoelasticity, 
we found that after 24 hours in hypoxic conditions, all constructs became significantly 
softer; stiff constructs reached 127±98Pa; medium constructs reached 61±60Pa; and soft 
constructs reached 4±4Pa (Figure 3-7B).  Gene expression analysis of the angiogenic 
factors vascular endothelial growth factor (VEGF) and angiopoeitin-1 (ANG-1) showed 
that hypoxia upregulated secretion of these angiogenic factors by the HT1080 cells more 
than atmospheric conditions (Figure 3-7C–D) also, we observed a greater upregulation of 
these factors in cells cultured in a 3D than in a 2D environment. These factors most likely 











  Figure 3-6. Effect of AHA-HT1080 on ECFC sprouting and invasion. 
 (A) Schematic of study strategy for examining the angiogenic potential of AHA-
HT1080 constructs: HT1080 cells, SDF1-α and S1P were encapsulated in AHA 
hydrogels of different stiffnesses and cultured for 24 hours in hypoxic or 
atmospheric conditions, followed by seeding of ECFCs as a monolayer on top of the 
hydrogels and culturing for an additional 24 hours. (B) Lectin stain (in red) and 
side-view imaging of endothelial sprouting in medium hydrogel in atmospheric and 
hypoxic conditions. (C) Quantification of sprouting length of ECFCs in the different 
stiffness and oxygen tension conditions. Significance levels (n=3) were set at: 







Overall, our results imply that oxygen tension influences 3D cultured HT1080 cells 
more profoundly than matrix stiffness. Encapsulated in the AHA hydrogels under hypoxic 
stress, HT1080 cells recovered from apoptosis better and demonstrated greater angiogenic 
 
Figure 3-7. Angiogenic gene expression. 
(A) Quantitative RT-PCR for the expression of MMP-1 in HT1080 cells cultured in 
Petri dishes (plates) or encapsulated in the different hydrogels for 24 hours. (B) 
Viscoelasticity measurements of the different construct types along the three-day 
hypoxic culture period. (C-D) Quantitative RT-PCR for the expression of VEGF, 
and ANG-1 in HT1080 cells cultured in Petri dishes (plates) or encapsulated in the 
different hydrogels for 24 hours. Significance levels (n=3) were set at: *p<0.05, 





induction. While it seems surprising that matrix stiffness plays a minimal role in 
determining cell fate and triggering the angiogenic capability of HT1080 cells, it is possible 
that conducting experiments over longer time periods or examining a wider viscoelasticity 
range would activate signaling pathways that are dependent on stiffness mechanism in 3D 
constructs. In the study of EC sprouting, it is worth noting that, without the addition SDF-
1α and S1P, we observed little or no sprouting, suggesting that other cell types in the tumor 
microenvironment secrete these two (or similar) growth factors. Candidates include 
stromal cells or leukocytes, which are recruited toward malignant cell sites and produce 
S1P or SDF-1 [136, 147]. 
Utilizing AHA hydrogels, we generated a well-defined 3D culture system to study 
the effects of matrix viscoelasticity and oxygen tension on cancer cell behavior. We found 
that encapsulation of 5 to 10 x 106 cells/ml generated DO gradients throughout the hydrogel 
matrix in atmospheric (21 %), hypoxic (5 %), and severely hypoxic (1 %) conditions. 
Encapsulation of low cell concentrations (1 x 106 cells/ml) maintained a uniform DO 
distribution under atmospheric and hypoxic conditions. We demonstrated that, using our 
3D AHA hydrogel culture system, encapsulated HT1080 cells recovered more rapidly from 
apoptosis under hypoxic conditions than under atmospheric conditions without obvious 
correlation to the matrix’s stiffness. We found that angiogenic induction correlated highly 
to decreases in matrix stiffness under atmospheric conditions, while hypoxia upregulated 
angiogenic responses in the stiffer hydrogels. Overall, we suggest that hypoxic pathways 
activation of HT1080 cells encapsulated in the 3D AHA hydrogel enables better cell 




comparing the responses of different cancer cell lines at different stages of tumorigenesis, 
supporting the basic study of tumor biology, and selectively impeding cancerous processes. 











4 Engineered human vascularized hyaluronic 
acid hydrogels to treat diabetic food ulcer wounds. 
 
Diabetic foot ulcers (DFUs) are a severe healthcare problem that poses a high risk in 
most diabetes patients. Current treatments are often lengthy and insufficient to prevent 
further complications. New therapeutic strategies aim to enhance blood vessel growth in 
diabetic patients. At the same time, stem cell therapy is emerging as a promising approach, 
especially for patient-specific treatment. Here, we propose to combine both angiogenesis 
and stem cell therapy, which could serve as a novel therapeutic modality by promoting 
neovascularization and wound healing in patients.  We first developed an immunodeficient 
diabetes mellitus rodent DFU model using streptozotocin (STZ). We then successfully 
engineered vascularized constructs by encapsulating various vascular cell sources (ECFCs, 
iPSC derived EVCs from a healthy patient, BC1 or a diabetic patient, T1D) in HA 
hydrogels. We tracked and analyzed the closure of the wounds with multiple assessments 
such as photometric measurements, blood flow profiles, histology, and a macroscopic 
wound healing rate model. We found that all vascularized constructs enhanced and 
expedited wound closures when compared to non-treated wounds. We also observed the 
best wound healing mechanics for the ECFC vascularized construct treatment followed by 




showcased a potential therapeutic strategy using a stem cell derived vascularized scaffold 




In humans, wound healing is a continuum of processes, which consists of several 
overlapping stages. These stages include inflammation, cell proliferation, migration, 
angiogenesis, re-epithelialization, and reconstruction of the extracellular matrix [149]. In 
diabetic patients, constant hyperglycemia can cause dysfunction at several stages 
throughout the wound healing process. For example, inflammation is prolonged and 
intensified due to the intrinsic high glucose environment, as the ability of macrophages to 
removed necrotic cells is diminished [150]. Hyperglycemia also induces alterations in 
cellular and molecular processes, such as growth factor, chemokine, and cytokine 
expression [151]. Abnormal granulation tissue formation has also been linked to impaired 
diabetic cutaneous wound healing [152]. Additionally, perpetual high glucose levels in the 
blood prevent proper blood flow to the extremities, which causes a lack of oxygen and 
nutrient supply, thereby limiting angiogenesis and altering the permeability of the 
vasculature [92].  Further, peripheral nerve damage, especially distal symmetrical 
polyneuropathy (DSP), is most commonly seen in this patient group [153, 154]. 
Neuropathy causes a lack of feeling in the extremities, leading patients to suffer from injury 
unawareness and repeated trauma [5]. Thus, patients often suffer from an impaired wound 
healing process and exhibit non-healing wounds, which consequently can lead to ulcers, 




The current standard of treatment for these recurring wounds includes improving 
blood glucose control and pain management [92].  However, in many cases this is not 
adequate, as non-healing diabetic ulcers have become a leading cause of non-traumatic 
amputation in the U.S [155]. The economic and health care burden as well as the decreased 
quality of life for the diabetic mellitus patients suggests a clear need to investigate 
alternative treatments for diabetic ulcers. 
Tissue engineering approaches pose possible solutions for treatment of impaired 
wound healing. For these applications, the construct materials need to be biocompatible. 
Additionally, it would be beneficial to vascularize the constructs. It is widely accepted that 
timely vascularization, is needed for successful regeneration of injured tissues, since 
vascularization supplies necessary oxygen and nutrients to support the renewal and 
differentiation of new tissue [156]. Previously, our group, along with many others, has 
utilized bioactive natural matrices to study the pre-vascularization potential of various 
human stem cells [77, 156-162]. Specifically, our group has demonstrated successful 
integration of engineered microvascular constructs consisting of endothelial colony 
forming cells (ECFCs; [82, 91]) or induced pluripotent stem cell (iPSC)-derived early 
vascular cells (EVCs) [89] in hyaluronic acid (HA) hydrogels, with the host circulation 
[89]. In recent studies, we have derived EVCs from type 1 diabetic patient (T1D)  iPSCs 
and demonstrated their functionality and ability to form networks in HA hydrogels [90].  
In this study, we hypothesized that our in vitro vascularized constructs would survive 
implantation into diabetic wounds and integrate with the diabetic host to reestablish blood 





4.2 Materials and Methods 
 
4.2.1 Differentiation Protocol and Cell Culture 
EVC expansion and differentiation from BC1 and T1D human induced pluripotent 
stem cell (hiPSC) lines followed our established protocols [89, 90]. Briefly, 
undifferentiated hiPSC (BC1 and T1D) were maintained on inactived mouse embryonic 
fibroblast feeder layers in growth medium with 80 percent ES-EMEM/F12 (Global Stem), 
20 percent serum replacement (Invitrogen), and 10ng/ml basic fibroblast growth factor 
(bFGF). For differentiation, hiPSCs were collected through digestion with EDTA 
(Promega), single cells were seeded and plated onto collagen IV (Trevigen)-coated cell 
culture plates with a concentration of 5 X 104 cell/cm
2 supplemented with 10µM ROCK 
inhibitor Y-27632 (Stemcell Technologies). Cells were cultured for 6 days in a 
differentiation medium composed of alpha-MEM (Invitrogen), 10% FBS (HyClone), and 
0.1 mM β-mercaptoethanol (β-ME), with the medium changed daily. Differentiated cells 
were collected through digestion with TrypLE (Invitrogen) on day 6 and seeded at a 
concentration of 2 X 104 cells/cm2 on collagen type IV-coated plates in endothelial cell 
growth media (ECGM) (PromoCell) supplemented with 2% FBS, 50 ng/mL VEGF with 
10 μM SB431542 (Tocris) for 6 days. The medium was changed every other day. ECFCs 
(Lonza) were cultured under the manufacturer’ss protocol. Briefly, cells were seeded and 
expanded in endothelial growth media EGM-2 (Lonza) and cells with passages 6 through 
8 were used for experiments, as previously described [89, 91]. 
4.2.2 Synthesis of Acrylated Hyaluronic Acid (AHA) Hydrogels Macromer 




AHA was synthesized in two steps: (1) the tetrabutyl-ammonium salt of HA (HA-TBA) 
was formed by reacting sodium hyaluronate (90 kDa, LifeCore Biomedical) with the ion 
exchange resin Dowex-100 (Sigma) and neutralized with 0.2M TBA-OF (Sigma); (2) 
acrylic acid (3 eq) and HA-TBA (1 eq) were coupled in the presence of 
dimethylaminopyridine (DMAP; 0.15 eq) and di-tert-butyl dicarbonate (3 eq) in DMSO, 
followed by dialysis and lyophilization. 1H NMR spectra were used to confirm the 
modification of the AHA. The cell-adhesive peptide GCGYGRGDSPG (RGDS, molecular 
weight [MW]: 1025.1 Da) and MMP-sensitive peptide crosslinker 
GCRDGPQGWGQDRCG (MMP, MW: 1754 Da) were purchased (Genscript, > 95% 
purity per manufacturer HPLC analysis.) 
4.2.3 Generation of Human Vascular Constructs from ECFCs and EVCs  
We engineered human vascular networks within the AHA hydrogels similar to our 
previous studies [82, 91]. AHA macromer was dissolved in triethanolamine buffered saline 
(TEOA buffer: 0.2M TEOA) at 3 wt%. Cell adhesive peptides (RGDS, GenScript) were 
dissolved in TEOA buffer and added to the AHA solution to the final peptide concentration 
of 4.8mM Recombinant human VEGF165 (Pierce), bFGF (Invitrogen), Ang-1 (R&D 
Systems), TNF-alpha (R&D Systems), and stromal cell-derived factor-1 (SDF-1; R&D 
Systems) were also added into the AHA-RGD mixture at 50 ng/ml. The mixture was 
allowed to react for 1 hour with gentle shaking.  For crosslinking, an MMP cross linker 
(MMP, GenScript) dissolved in TEOA buffer was added to a final concentration of 5.15 
mM. Preconditioned ECFCs and EVCs were encapsulated in AHA hydrogels at a density 
of 5 X 106 cells/ml by suspending the cells in the AHA-RGD solution as described above 




pipetted into sterile molds (5 mm diameter, 2 mm height) and allowed to react for 10 
minutes at room temperature in a laminar flow hood. The constructs were then cultured in 
ECFC culture media in the conditions described throughout the study. 
 
4.2.4 Streptozotocin (STZ) Induced Diabetes Mellitus Nude Mice 
The standard protocol for STZ induced diabetes mellitus provided by Animal 
Models of Diabetic Complications Consortium was followed [92-94]. Nude mice at about 
2-2.5 months of age (about 20-25 g body weight) were randomly assigned to a diabetic or 
a non-diabetic group. Animals in the diabetic group were induced by 5 intraperitoneal 
injections of STZ at a dose of 50 mg/kg body weight (STZ is freshly dissolved in citrate 
buffer, pH 4.5). Prior to injection, mice were fasted for 4 to 6 hours. The weight and blood 
glucose of each mouse were checked daily for up to 2 weeks after the STZ injection. 
Successful STZ-induced diabetic mellitus nude mice were confirmed by two consecutive 
blood glucose levels readings higher than 300 mg/dl over a 48 hour period. Blood glucose 
was measured using an Accuchek blood glucose meter (Roche) by obtaining 20-25μl of 
blood from a tail vein puncture (30 gauge needle). 
4.2.5 Diabetic Foot Ulcer (DFU) Animal Model and Vascularized Construct 
Transplantation 
DFU animal model was constructed by incorporating various protocols from the 
literature [92, 95-98]. After diabetic mellitus was confirmed, diabetic induced nude mice 
were anesthetized with isoflurane (Thermo Fisher). A depilatory was applied (Nair), prior 
to wound creation, to ensure better dressing adherence. Next, 2 x 6mm diameter punch 




skin on each side of the posterior dorsum. Vascularized constructs, which were generated 
in vitro, were then transplanted into one side of the animal (one per wound). The time point 
was logged as day 0 post-wound. Betadine was applied around the periphery of the wound 
to enhance dressing adherence. The wound on the opposing side was left with no 
vascularized construct treatment. Both wounds were then covered with Tegaderm dressing 
(3M). 6 to 8 constructs were implanted for each group at each time point. At each time 
point of interest, as described below, human specific fluorescein- conjugated Ulex 
europaeus I (UEA-I) Lectin (1:10; Vector Laborato) and mouse-specific rhodamine-
conjugated Isolectin Griffonia simplicifolia (GS)-IB4 (1:10; Invitrogen) were injected 
through the tail veins of the mice [82, 89, 91]. After 30 minutes, the mice were euthanized, 
and the constructs were harvested and fixed in 3.7% formaldehyde (Sigma). The tissue was 
processed for immunohistochemistry or histology. The Johns Hopkins University 
Institutional Animal Care and Use Committee approved all animal protocols.  
4.2.6 Bloodflow and Planetary Measurement 
During the study, the blood flow profiles inside the wounds were monitored 
noninvasively using moorFLPI speckle contrast imager (Moor Instruments, Inc.). The 
measurements were normalized by the blood flow measurements of the adjacent healthy 
skin area. Photometric analysis of wound closure rate was done along with blood flow 
measurement.  
 
4.2.7 Immunohistochemistry and Histology Analysis 
Following fixation of the explants, the samples were dehydrated in serial ethanol 




hematoxylin and eosin (H&E) stain or immunoperoxidase stains for anti-mouse alpha-
smooth muscle actin (alpha-SMA) (Abcam), or anti-human CD31 (Dako). Double staining 
was performed using the same anti-human CD31 and anti-mouse alpha-SMA followed by 
conjugation with anti-mouse Alexa Fluor 488 (Life Technologies) or anti-rabbit Alexa 
Fluor 564 (Life Technologies) and counter stain with Dapi. Histological images were taken 
with an upright light microscope (Nikon Accuscope 3000) and a camera (Nikon DS-F12). 
4.2.8 Statistical Analysis and Regression fit 
Statistical analysis was performed using GraphPad Prism 6.01 (GraphPad Software 
Inc.), A non-linear regression fit, One Way ANOVA with Tukey’s posttest, or Two Way 
ANOVA with Bonferroni’s posttest were used where appropriate. Analysis consisted of t-
tests, in which significance levels were set at *p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001. Unless otherwise indicated, all graphical data are reported SD. 
4.3 Results  
4.3.1 Immunodeficient Diabetes Mellitus Rodent DFU Model 
We have previously reported that AHA hydrogels can be engineered to support 
functional human microvascular networks with either ECFCs or EVCs [82, 89]. We have 
also reported that AHA in vitro formulated microvasculature can be delivered to the site of 
deep burn injury models. Here, we sought to investigate the treatment applications of our 
in vitro microvasculature in diabetic wound healing.  The STZ-induced diabetic mouse 
model is one of the most extensively used models in diabetic wound repair and provides a 
deep understanding of diabetic wound healing [97, 98, 163-166]. Since we are delivering 




rodent model in order to further investigate our microvasculature’s therapeutic potential. 
We followed standard protocol suggested by Animal Models of Diabetic 
Complications Consortium for inducing a diabetic animal using streptozotocin (STZ; [92-
94]). We tested both a single large STZ dose (150 mg/kg body weight) and multiple low 
STZ doses (50 mg/kg body weight). Both methods successfully induced diabetic nude 
mice, however, the single large dosage had a higher mortality rate after 14 days from the 
time of the first injection (data not shown). The higher dosage would have limited the 
length of the study, thus we opted for multiple low dose induction protocol (Figure 4-1A). 
Animals received daily STZ injection for 5 days. Their blood glucose levels rose around 
one week following their first injection (Figure 4-1Bi). At the same time, their body weight 
dropped about 15~20% (Figure 4-1Bii), correspondingly. We also noticed variation of drug 
tolerances in different batches of animals. However, more than 80% of all animals 
receiving STZ were successfully induced (not shown).  
We next aimed to mimic diabetic foot ulcer wounds in order to test the therapeutic 
potential of the engineered human vascular constructs. Following successful diabetic 
mellitus (confirmed by 2 consecutive readings separated by 48 hours), we removed 2 X 
6mm full thickness skin biopsy punches at the dorsum region of the animals. One served 
as a treatment group and the other served as a paired non-treatment control. Human 
vascular network constructs were generated during the induction period. Constructs were 
placed into the wounds and layered with Tegaderm to enable their placement and to 
maintain a moist and sterile environment during would healing (Figure 4-1C).  This setup 
also enabled us to observe and monitor skin closure as well as blood flow measurement 





Figure 4-1. Diabetic immunodeficient mouse model 
(A) Schematic drawing of our DFU immunodeficient diabetic mellitus animal 
model. (B) Blood glucose measurements (i) and corresponding weight of the animals 
(ii) during the experimental period. 300 mg/dL is considered diabetic (C) (i) Wound 
creation after bandage using betadine and tegaderm and (ii) planetary 





4.3.2 In vitro Microvascular Networks from Varies Cell Sources 
We recently developed a robust and controlled method to differentiate hiPSCs, 
sourced from healthy and Type 1 diabetic patients (T1D), into a bicellular vasculogenic 
population of both endothelial cells (ECs) and pericytes [89, 90]. Together with our already 
established adult progenitor cell source (ECFC), we established 4 different test groups 
(Figure 4-2A). Groups ECFC, EVC- BC1 and EVC-T1D were of constructs generated with 
corresponding vasculogenic cell sources [82].  The acellular construct group, Group AHA, 
were treated with AHA hydrogels encapsulated with growth factors. All constructs were 
cultured under the same conditions in vitro for 72 hours. In the cellular constructs, we 
observed vacuole formation on day 1, marked with red arrows, followed by capillary like 
microvasculature (multicellular network structures longer than 100µm) formation on day 
3 for all three cellular treatment groups (Figure 4-2B). 
4.3.3 Macroscopic Wound Closure and Bloodflow Profile 
We closely followed the progress of  wound closure for all groups at various time 
points. Complete wound closure occurred within  2 weeks following treatment. By week 
2, wounds treated with acellular constructs were mostly closed while some of the no-
treatment (NT) wounds were not fully closed.  When treated with acellular constructs, 
wounds healed about 2 to 3 days faster than wounds that received NT (Figure 4-3A). 
During the 2 week period, all treatments accelerated wound closure significantly when 
compared to NT control. Planetary photos of day 7 following treatment found that the 
largest open wounds remained in the NT wounds, followed by wounds treated with the 
acellular constructs. The difference in wound size between wounds treated with EVC-BC1 




wounds treated with ECFCs (Fig 3Bi). Correspondingly, when treated with 
microvasculature constructs, EVC-BC1 and EVC-T1D constructs induced wound closure 
at a similar rate, while wounds treated with microvascular constructs composed of ECFCs 
closed at the fastest rate among all treatment groups (Figure 4-3B).  
We further preformed blood flow measurements along the treatment period. 
Measurements on day 3 were neglected since the machine was reading the muscle layer 
underneath the wound bed. On day 5, we observed significantly higher blood flow in all 3 
groups that received the microvessel construct treatment (Figure 4-3C). Both NT wounds 
and wounds treated with acellular constructs had lower blood flow readings compared to 
wounds treated with the cellular constructs. Interestingly, on day 7, we observed a delayed 
increased bloodflow in wounds treated with acellular constructs. Notably, wounds treated 
with cellular constructs (ECFC, EVC- BC1/T1D) all had higher blood flow readings when 


















Figure 4-2. Experimental groups and in vitro engineered human vascular 
constructs.  
(A) Treatment groups for DFU using acellular (AHA) and cellular (ECFC, EVC- 
BC1, EVC-T1D) vascularized constructs. NT=no treatment (B) in vitro cultures of 
the microvascular constructs at day 1 and day 3. Vacuoles are marked as red 





 Figure 4-3. Macroscopic analysis for diabetic wound healing. 
(A) Closure of wounds treated with acellular constructs and wounds receiving no-
treatment: (i) planetary photos of wounds at day 3, 7 and 14; (ii) wound closure 
progression along the treatment period. (B) Closure of wounds treated with 
microvascular constructs and wounds receiving no-treatment: (i) planetary photos of 
the wounds at day 3, 7, and 14; (ii) wound closure progression along the treatment 
period. (C) Blood flow profile of different treatment groups at time intervals along the 
treatment period. Note that here we consolidated all NT controls together from all 
other control groups because significant differences were not observed between them. 







4.3.4 Wound Healing Rate Analysis 
Healing of tissue wounds has been extensively studied using mathematical 
modeling [167-170]. In our studies, the wound closure profiles closely matched theprofile 
of a logistic function. This allowed us to quantitatively model the wound healing using a 
mathematical equation to represent the time course of the healing and allowed us to study 
the underlying biological events. We chose a logistic growth curve to macroscopically 
model our wound healing profile, which not only provided an accuratefit, but also provided 
biophysical significance and predictive capability.  
The equation below is written as for a non-linear regression fit, where y represents 
the progression of wound healing (in terms of percent skin closure), which corresponds to 
the open wound size % from (Figure 4-3ai) and (Figure 4-3bi).  t represents the time post 







The computed regression fit parameters are shown in Table 1.  Goodness of fit of the 
regression model to our diabetic wound healing data is reported by the given R-squared 
value (Figure 4-4A). The parameter α stoichiometrically represents the intrinsic skin 
closure rate and the parameter β indicates the time to reach the maximum closure rate. We 
can compare different treatment groups by analyzing the parameters through a t-test (Table 




(second derivative) profiles (Figure 4-4B-C) to visualize the closure rate profile and the 
healing acceleration profile. We found that all three cellular treatments groups (ECFC, 
EVC-BC1 and EVC-T1D) healed at a similar rate. In other words there were no statistically 
significant differences between the healing rates of the cellular treatment groups. All 
cellular treatments groups reached maximum peak closure rate significantly sooner when 
compared to the acellular and NT groups (Table 4-1). Wounds treated with ECFC had the 
earliest maximum closure rate when compared with EVC-BC1 and EVC-T1D treatments, 
however, there were no significant difference between wounds treated with EVC-BC1 or 
EVC-T1D in terms of both healing rate and the time to reach maximum rate.  Wounds 
treated with acellular AHA constructs healed at a more accelerated manner (less time to 
reach maximum) and also greater in magnitude compared to the NT wounds (Figure 4-4B-











Figure 4-4. Would healing model profile, velocity and acceleration.  
(A) Wound healing fitted model. Circles represent mean value of wounds healed at 
given time point from experimental results. Color lines are numeric value from the 
fitted model. (B) Velocity profile from first derivative of fitted model and (C) 
Acceleration profile from second derivative of the fitted model for assessment of 





Table 4-1. Wound healing fitted curve parameters and regression fitness 
 NT ECFC BC1 T1D AHA 
 Value SD Value SD Value SD Value SD Value SD 
Α 0.591ebta 0.119 0.818na 0.067 0.844na 0.126 0.793na 0.054 0.720ebtn 0.037 
-β 6.560ebta 0.377 4.770btna 0.113 5.541ena 0.199 5.532ena 0.094 5.233ebtn 0.081 
R2 0.922 0.990 0.972 0.995 0.996 





In this study, we first established an immunodeficent diabetic wound healing murine 
model for examining the therapeutic potential of our prevascularized constructs. We 
utilized STZ, a compound that has toxicity targeting the pancreatic β cells [94]. Inducing 
STZ in nude mice provided a platform to transplant human cell constructs and to test these 
constructs in an animal wound healing model. In establishing our model, we noted that the 
survival of nude mice following STZ treatments posed a greater challenge when compared 
to the wild type mouse, and literatures has shown the efficiency of induction is also varies 
from different source [171]. With a one-time high dose injection method, in our case, nearly 
100% of mice develop diabetes within a week, however the high dose also leads to a high 
mortality rate 1 week after STZ injection and animals fail to survive past week 2. On the 




induction results, with low mortality rates and a relatively high rate of successful induction.  
To study wound healing, many animal methods have been developed; one of the 
methods that has been extensively utilized to replicate human physiology is the splint 
model [95, 172, 173]. In the splint model, a circular splint, typically made of silicon, is 
attached with super glue and sutures on the uninjured skin around the wound to prevent 
wound contraction. This model addresses the contraction issues, which are a major 
difference between the human and rodent healing mechanisms. The splint wound was 
mostly used to test wound healing on the db/db mouse strain [174]. This specific strain has 
a baseline weight higher than many other mouse strains. This weight increase results in 
sluggish and slow movement of the animals, which is crucial for the splint to stay intact 
[173]. We tested the splint model in our STZ-induced nude mice and found that the splint 
lost its adherence after 5 days post operation due to the active nature of the nude mice. The 
usage of instant glue to better adhere the splint to the skin promoted scratching and further 
reduced the adherence of the splint after the glue lost its adherence. Consequently the splint 
was only left intact with sutures to the mouse skin. However, we found there was no 
significant difference between splinted vs un-splinted wounds (data not shown). A possible 
explanation is that the combination of betadine and tegaderm layered to seal the wound 
acted in a similar manner as the silicon splint. As a result, we simplified the procedure and 
treated the wounds without applying the splint, in so assuming the contraction rate 
remained the same magnitude throughout all experimental groups.   
After establishing the diabetic wound healing model, we generated prevascularized 
constructs in AHA hydrogels with selected cell sources. We showed that all ECFCs and 




protocols [82, 89, 90], to form microvascular like structures. After implantation, we closely 
followed the wound healing process. Acellular treatment with hydrogel alone still 
enhanced the healing compared to NT. Vascularized constructs also enhanced healing. 
Among them, ECFC microvasculature enhanced closure the fastest compared to EVC-BC1 
and EVC-T1D constructs. This may be attributed to the maturation stage of the cells; while 
ECFCs are progenitors derived from the cord blood, EVCs are derived from hiPSCs and 
are a less mature cell type. Examining the blood flow profiles, it is clear that the presence 
of implanted microvasculature facilitated faster blood perfusion, especially during the first 
week compared to acellular constructs and NT. From the histology sections, we found that 
non-degraded hydrogels remained in the wounds treated with acellular constructs, which 
may have hindered the blood perfusion toward the center of the wound. It is interesting to 
notice that wounds treated with ECFCs or EVC-BC1 constructs exhibit higher blood 
perfusion at all the time points. In wounds treated with EVC-T1D constructs, blood flow 
regresses after day 10. However, we were unable to follow the wound closure longer than 
3 weeks to assess skin maturity in long term due to the poor health of the immunodeficient 
mice. The differences between ECFC and EVC-BC1 with EVC-T1D could be due to the 
genetic nature of the T1D. The hyperglycemia of the host could trigger a sequence of 
epigenetic events which cause vessel regression, which may damage the integrity of the 
vascular network.  
Next, we used a non-linear logistic growth model to fit our diabetic wound healing 
profile. It allowed us to compare the healing progression of the wounds between treatment 
groups. We decided to use a supermacroscopic approach [168]. This approach focused on 




the tissue level, where in our case was the size of the healed wound. We found that wounds 
treated with vascularized constructs healed at a faster rate, possibly because of increased 
blood flow. In the case of treatment with acellular constructs, wounds still healed faster 
than NT, where the contributing factor could be has lesser time to reach maximum closure 
rate. This could be attributed to the hydrogel providing a scaffold for cell migration towards 
the wound site, thereby enabling healing. This increased wound healing response may also 
have been due to the growth factors encapsulated in the hydrogels, which are known to 
activate wound healing pathways. It is worth noting that our approach poses limitations 
when compared to a microscopic approach [167] where the variables and relations were 
constructed at the cellular or molecular level. As a result, we do neglect the individual 
cellular mechanisms during wound healing. We can then only make indirect observations 
of relationships between the experimental data and our experimental groups. This analysis 
limits us to draw direct connections at a macroscopic level, rather than at acellular level. 
However, this supermacroscopic strategy is sufficient to provide quick and direct insight 














5 Acellular hydrogels for regenerative burn 
wound healing: translation from a porcine model 
 
Healing following third-degree burn injuries is fraught with complications, often 
resulting in long-term physical and psychological sequelae. The use of currently available 
skin grafts and skin substitutes are often associated with complications and suboptimal 
outcomes. Synthetic treatment that can promote wound healing in a regenerative fashion 
would provide an off-the-shelf, non-immunogenic strategy to improve clinical care of 
severe burn wounds. Here, we demonstrate vulnerary efficacy of our dextran-based 
hydrogel in third-degree burn wounds in a large-animal model. This porcine model was 
optimized to allow examination of the hydrogel treatment for clinical translation and the 
mechanisms by which it promotes a regenerative response. Hydrogel treatment accelerated 
third-degree burn wound healing by rapid wound closure, improved reepithelialization, 
enhanced extracellular matrix remodeling, and greater nerve reinnervation, compared to 
the dressing treated group. These effects appear to be mediated through the ability of the 
hydrogel to facilitate a rapid but brief initial inflammatory response that coherently 
stimulates neovascularization within the granulation tissue during the first week of 
treatment, followed by an efficient vascular regression to promote a regenerative healing 
process. Our results demonstrate that the dextran-based hydrogels, without the use of 




grafting incidents and thus pave the way for clinical studies to improve the care of severe 




Burns are a leading cause of accidental death that when survived, can result in serious 
disability and social impairment from disfigurement [175]. In 2013, approximately 
450,000 burn injuries received medical treatment [176] and the estimated hospital care cost 
in high-income countries estimated to exceed $88,000 per burn patient [177]. In the United 
States, only ~4% of patients admitted to burn care centers die, and due to advances in 
critical care and medical management of these patients, survival has continued to improve 
with time [89]. Survival in the most severely burned patients is often accompanied with 
orthopedic, neurologic and metabolic complications and significant psychosocial 
challenges brought about by poor healing and excessive scar formation [178]. Therefore, 
the challenge remains to improve wound healing in the patients in order to reduce 
morbidity and mortality in those patients with the worst burns—those classified as third-
degree burns and beyond. Third-degree burn wounds are characterized by the full-thickness 
damage of the skin, including both the epidermal and the dermal layer. Unlike superficial 
burn wounds that can heal on their own without advanced professional care, third-degree 
most often require surgical intervention and replacement of damaged skin with skin grafts 
or skin substitutes [179]. Biomaterials that are able to induce a regenerative response of 
healing would therefore promise significant improvement in clinical care and long-term 




Predicting which therapeutic interventions will elicit a regenerative response post-
cutaneous wounding has remained challenging. Although murine models are irreplaceable 
for understanding mechanisms involved in normal and pathologic wound healing, mice, 
unlike humans, heal primarily by contraction. Additionally, there may be differences in the 
immune/inflammatory response to cutaneous injury, particularly that of burn injury [180], 
and the lack of significant naturally occurring pathologic scar formation in mice. Porcine 
wound healing is considered to be most similar to that of humans and as a translational 
model, pigs display the greatest concordance with human trials [181]. The Yorkshire pig 
is a well-established model that approximates the normal wound healing response in 
humans [182].  First, porcine skin most closely resembles human skin both anatomically 
and physiologically. Both have similar dermal-epidermal thickness ratio and dermal 
vascularization pattern [181, 183]. Biochemically, porcine and human skins have similar 
collagen matrix and keratinous proteins [175]. Studies have also shown an excellent 
agreement between pig and human with respect to wound healing responses from growth 
factors [181]. In addition, the size of the animal allows control and comparison of different 
treatment parameters in the same animal. Despite these benefits, technical difficulties limit 
the use of pig models for studies of third-degree burns. Indeed, unlike superficial burn 
wounds, which can easily be created using accessible tools and temperatures, there is 
limited literature on modeling severe burn injuries in a reproducible manner and on the 
criteria for assessing the healing kinetics, especially for the purpose of evaluating 
biomaterials.  
Our laboratory has developed an acellular dextran-based hydrogel, dextran-allyl 




to accelerate third-degree burn healing with complete skin regeneration in a murine model 
[85-87]. We have shown that compared to other treatments, the dextran-based hydrogel 
better promotes rapid neovascularization through its ability to facilitate infiltration and 
resolution of an early inflammatory response, leading to complete skin regeneration. This 
current translational study extends our understanding of the mechanisms of dextran-
hydrogel induced healing in a porcine large-animal model and shows that dextran-based 
hydrogel alone, without the use of additional biologicals such as growth factors or cells, 
can safely promote a regenerative healing and thus paves the way for their use in clinical 
studies.  
 
5.2 Materials and Methods 
 
5.2.1 Polymer Synthesis and hydrogel preparation 
The dextran hydrogel was synthesized and characterized as previously [85-87]. Briefly, 
allyl isocyanate (AI) was incorporated into dextran by dissolving pre-dried dextran (e.g. 
2g) in anhydrous DMSO (20mL) at room temperature under nitrogen gas. Reaction catalyst 
DBTDL was added (0.210mL), and AI (0.240 mL) was added to the solution dropwise. 
After the reaction, the solution was precipitated in cold excess isopropanol and filtered. 
Next the remaining hydroxyl groups in Dex-AI were substituted with ethylamine groups. 
For this step, pre-dried Dex-AI (e.g. 2g) was first dissolved in DMSO (30ml) under 
nitrogen gas. Meanwhile, BEAHB (3.75g) was dissolved in DMSO (10ml) in a separate 
chamber. Catalyst TEA (11.2mL) was added to the Dex-AI DMSO solution, and the 




salt was filtered and the resulting solution was precipitated in cold excess isopropanol and 
filtered. The resulting Dex-AE was then dialysized against distilled water for 3 days and 
lyophilized for additional 3 days. The purified polymer was stored in vacuum until further 
use. For characterization NMR of the polymer for degree of substitution for thiol group 
(AI) and aminated group (AE) was performed. For crosslinking, polyethylglycol diacrylate 
(PEGDA) was synthesized as previously established and dialysized against distilled water 
for 3 days and lyophilized for additional 3 days. The purified polymer was stored in 4°C 
until further use. For hydrogel preparation Dex-AE and PEGDA were dissolved at the 
weight ratio of 80:20 into phosphate-buffered saline containing 0.1% (w/w) Irgacure® 
2959. The mixture was pipetted into a sterile mold made by polydimethylsiloxane and 
photocrosslinked (10mW/cm2 of UV light for 10 minutes). Hydrogels were swelled against 
PBS for swelling ratio and crosslink density characterization. In vitro cell toxicity was 
carried using WST assay (Sigma) as well as pilot in vivo burn mice tests [87] were done to 
confirm AE hydrogel therapeutic properties.  
 
5.2.2 Animal use and surgical procedure 
Surgical procedures were approved by the Institutional Animal Care and Use 
Committee at Thomas D. Morris, Inc. prior to the experiments. All pigs were fasted for at 
least 12 hours prior to any surgical procedure. Anasthesia was induced by an intramuscular 
injection of Telazol cocktail reconstituted with ketamine and xylazine. Then, the pig was 
endotracheally intubated and ventilated mechanically to aid breathing and to provide up to 
1.5% of isoflurane (depending on the painfulness of the procedure) to maintain anasthesia. 




monitored. Bair Hugger® was placed under the pig and set to 43°C to maintain a normal 
body temperature.  
Two pigs were used to determine optimal wounding procedure and parameters for third 
degree burn. Temperature was set at 100 and 200 degree Celsius while maintaining contact 
pressure at 2kg/cm2 and contact duration of 30 seconds. Biopsy was taken 24 and 48 hours 
after injury for histological analysis.  
Three pigs were then used to investigate the therapeutic effect of dextran hydrogel on 
burn wounds. Following injury, the wounds were left for 48 hours for stabilization before 
the excision procedure. A total of 70 circular third-degree burn wounds (1.2 or 1.5cm in 
diameter) were created. Circular biopsy punches were used for partial or complete excision 
for full-thickness wound down to the necrotic adipose layer. Wounds were at least 3cm 
apart from one another to minimize hindered wound healing process due to proximity. 
After the excision procedure, wounds were cleaned with sterile gauze to temporarily stop 
bleeding. Half of the wounds were treated with dextran hydrogel and the other half were 
left untreated. Hydrogels were crosslinked in molds that matched the size of the excised 
wounds. Treated and untreated wounds were first sealed with Tegaderm® (3M). The 
peripheries of the wound site was applied with compound benzoin tincture (Medical 
Chemical, Corp) to enhance the Tegaderm® adherence to the skin. An additional layer of 
Vetrap® (3M) was applied to the torso and elastic body suit (VetMedCare) were worn over 
the body in order to minimize the disturbance of the healing wounds.  To protect the newly 
forming epidermis from traumatization during bandage change, a non-adhesive Curity® 
dressing (Covidian) was placed under the Tegaderm® layer beginning at day 14. After 




debridement was made and a new half the thickness hydrogel was placed on top for 
retreatment. Secondary excision was made on control group as well for the retreatment 
group. Dressings were changed three times a week until wound closure was complete. 
Before the dress change, the pig was put under anesthesia with an intramuscular injection 
of Telazol cocktail reconstituted with ketamine and xylazine. The pig did not receive 
isoflurane because the procedure was quick. Before reapplying dressings, the wound area 
was scrubbed with 4% chlorhexidine and ethanol. The area was wiped with dry gauze and 
new dressings were applied.  
 To evaluate healing, skin specimens were biopsied at each time point as complete 
horizontal cross-sections of approximately 5cm in thickness with a sterile blade. 
Analgesics were administered before wound creating and biopsy procedures, and 
transdermal fentanyl patch was applied for 9 days post-operation.  Blood tests were 
performed regularly to monitor the pig’s health throughout the study.  
 
5.2.3 Healing Evaluation 
During the study, the blood flow inside the wounds were monitored noninvasively 
using moorFLPI speckle contrast imager (Moor Instruments, Inc.). The measurements 
were normalized by the blood flow measurements of the healthy skin area adjacent to each 
wound. Photometric analysis was done along with blood flow measurement.  
For immunohistochemical assay, collected skin specimens were first fixed with 10% 
formalin (Fisher Scientific, Inc.) for at least 48 hours. Following fixation, samples were 
dehydrated in graded ethanol (70% to 100%), embedded in paraffin, sectioned at 5μm or 




Gieson's stain or immunohistochemistry for CD31 (1:50 Abcam), cytokeratin 14 (1:50 
Abcam), MAC387 (1:50 Abcam), SMA (1:100 Dako), Dapi (1:1000), PGP9.5 (1:500 AbD 
Serotec) and matching Alexaflour secondary (1:500 Lifetech). Histological images were 
taken with upright light microscope (Nikon Accuscope 3000) and Camera (Nikon DS-
F12). Full specimens images were scanned and tiled together using automated motor 
controlled Nikon T1 and tiled together with corresponded software (Nikon Nis-Element). 
Fluorescent images were taken with confocal (Zeiss LSM780).    
The area and number of vessels inside the wounds were quantified using ImageJ 
software (National Institutes of Health) with histology sample of each wound stained with 
CD31. The vessels were imaged at the edges, middle, and top portions of each wound, and 
the positively stained areas were selected using the software’s threshold function. The 
selected areas were then quantified using “Analyze Particles” plugin of ImageJ. 
“Microvessels” with areas less than 78μm2 were excluded to filter out noise.  
Wound gap area was measure photometrically by tracing the opened wound edge using 
Image J. Histologically analysis for the maturation of the re-epithelialization is quantified 
by rete ridge formation density as previously described [99]. In brief, we first defined the 
entire wound length as the length between the two edges of the healthy dermis and 
epithelium. Then, re-epithelialization was calculated as the percentage of regenerated 
epithelium (K14 positive) of the entire wound. Percent reticulation is calculated as the 
percentage of the reticulated epithelium of the regenerated epithelium. The reticulated 
epithelium is defined as the epithelium from the first structural reticulation ridge to the last 
reticulation ridge within the wound. Rete density is calculated as the amount of reticulation 




Collagen fiber deposition was quantified from Masson trichrome images by calculating 
the percentage of collagen fiber presented in the wound. Briefly, using ImageJ, we 
quantified the percentage of stained collagen fibers in the given area in each group. Elastin 
fibers were quantified from Verhoeff-van Gieson's stain across the dermis area adjacent to 
the epidermis similarly to the collagen.  
Nerve innervation analysis was performed on a 25µm paraffin sections on gelatin 
coated slides. Samples were incubated in primary antibody overnight and 1 hour in 
secondary antibody. Slides were then analyzed in confocal using serial z-stack imaging. 
Final images were maximum intensity projected through z axis for the final images.  
 
5.2.4 Gene Expression 
Gene expression analysis was performed using two-step reverse transcription 
polymerase chain reaction (RT-PCR) on wound specimens in accordance with Applied 
Biosystems manufacturer instructions. To extract RNA, a small specimen was collected 
from each wound at different time points and snap-frozen in liquid nitrogen. The specimen 
was crushed with pestle and mortar, and the powdered sample was put in 1mL of Trizol 
reagent and stored in -80°C until further use. Wound healing and ECM RT-PCR array sets 
(Qiagen) were used to compare the expression profile inside the treated and non-treated 
wounds at different time points. For each primer, the comparative computerized method 
provided by the manufacturer was used to calculate the amplification differences between 





5.2.5 Statistical Analysis 
For wounding parameter determination two pigs were used. For wound healing 
analysis, total of three pigs with n>12 wounds for each condition with at least n=3 for each 
time point detailed throughout the manuscript. For quantification of blood vessels and 
reepithelialization whole wounds analyzed as detailed above. Real-time RT-PCR 
performed on triplicate samples (n=3) with triplicate readings. Statistic was calculated by 
the computerized method provided by the manufacturer to obtain p-value of the gene 
expression. For data presentation relative gene expression was graphed with relative fold 
change of the targeted group / dressing day 5. For all other assays, statistical analysis was 
performed using GraphPad Prism 6.01 (GraphPad Software Inc.) to perform t-tests, One 
Way ANOVA with Turkey’s posttest, or Two Way ANOVA with Bonferroni’s posttest 
where appropriate. Significance levels were set at *p<0.05, **p<0.01, ***p<0.001, and 






5.3.1 Dextran-based hydrogels for third-degree burn wounds in pigs 
To produce dextran-based hydrogels, dextran polymer was first modified with allyl 
isocyanate and ethylamine functional groups and cross-linked with polyethylglycol 
diacrylate [85-87]. The cross-linking density, controlled with low degree of substitution, 
was optimized to give high porosity and flexibility to the hydrogel in order to promote 
rapid inflammatory and angiogenic cell infiltration. Consistent with its synthetic and xeno-
free composition, the dextran-based hydrogels are nonimmunogenic and thus can be used 
as an off-the-shelf therapy. Compared to other formulation and treatments, the dextran-
based hydrogels accelerate wound healing in subcutaneous and burn wounds in murine 
studies, providing promising proof of principle evidence that dextran-based hydrogels 
promote a regenerative response post injury.   However, compared to mouse skin (0.1-
0.2mm), pig skin has a much thicker epidermal and dermal layers (3-4mm total) which, in 
addition to other anatomic features, is more similar to human skin. Therefore, the murine 
cutaneous anatomy protocol for creating third degree burn wounds in a mouse model was 
not sufficient in creating burn wounds at a third degree level.  
In order to investigate the safety and efficacy of the dextran-based hydrogel in the 
porcine third-degree burn injury model, we designed a custom-made device that was 
inspired from a previous study [184]. This device which is comprised of three parts 
including metal heat source, and insulation and pressure units (Figure 5-1Ai), allows for 
reproducible delivery of the critical components known to influence extent of thermal 




object [185] and to a lesser extent pressure [186].  The metal rod is being heated and used 
for generating the thermal injury. A digital thermometer probe placed within a predrilled 
hole is used to monitored metal rod’s core temperature for consistent thermal injury source. 
The middle part is an insulating unit made of polytetrafluoroethylene for holding the device 
upright for the duration of the burn. The air trapped in the syringe unit provides a spring 
force when pressure is applied, which can be measured and kept constant for all wounds.  
To create the wounds, the device was held at a 90° angle to the skin with a constant 
pressure of 2kg/cm2 (Figure 5-1Aii). A standardized anatomic position (thoracic 
paravertebral zone) was chosen based on its relative protection against post-burn self-
trauma associated with movement and recumbancy. As significant thermal insult is 
associated with progressive injury to deep tissues compared to superficial damages until 
48 hours post-injury [187], the degree of burn damage was evaluated in wounds 24 hours 
or 48 hours after the burn [184, 188]. Healthy porcine skin tissue sections are provided in 
(Figure 5-2) for reference. To induce full thickness dermal injury, a heat source of 200°C, 
applied for 30 seconds was required (Figure 5-1B). In contrast, application of a heat source 
of 100°C for either 30 or 60 seconds (Figure 5-1B; data not shown for 60 seconds) was not 
sufficient to induce a third-degree burn injury. As anticipated, evidence of dermal injury 
progressed between 24 and 48 hours. Thus, use of 200°C for 30 seconds was chosen to 
generate third-degree burns in assessing the ability of the dextran-based hydrogel to 
improve healing of burn wounds.  The significant damage induced by thermal injury in this 
model is evidenced by the reduction in blood flow, indicating more severe damage on blood 
vessels (Figure 5-1C-D). Immunohistochemistry for CD31 confirmed the lack of blood 




seconds (Figure 5-1E). Given the previously defined ability of this biomaterial to induce 
angiogenesis, the optimized burn model provides a rigorous model of injury with severe, 








Figure 5-1. Induction of third degree burn injury in pigs.  
(A) A custom-made burn device (i) is held upright on the pig’s thoracic 
paravertebral zone (ii). (B) Representative images of H&E and mason trichrome 
histological stains of the wounds at different temperatures and burn durations. (C-
D) Laser speckle contrast images (left) and quantification (right) of blood flow in 
healthy skin and burn wounds burn wound. N= 22 and N=8 for 200°C and 100°C 
respectively.  (E) Immunohistochemistry for CD31 of the 200°C 30 seconds 48h 
show no vessels in the wounded area compared to healthy skin. Scale bars are mm 
in B, 1cm in C and 100m in D. Significance levels were set at *p<0.05, **p<0.01, 
***p<0.001, and ***p<0.0001 
 
Figure 5-2. Healthy pig skin.  
Representative images of H&E (left) and trichrome (right) histological stains of 




5.3.2 Vascular ingrowth, maturation, and regression in hydrogel-treated burn 
wounds 
Following excision of the necrotic tissue, hydrogels were applied as skin substitutes. 
Because complete excision of the avascular zone of coagulation has been shown to improve 
outcomes when biomaterials are used for burn wound treatment, we investigated whether 
it was necessary for maximal efficacy to resect beyond the original injury site (complete) 
or whether a more conservative resection (partial) would be sufficient. In the first protocol, 
we followed the approach used in our previously published murine burn model in which a 
1.2 cm diameter biopsy punch was used to excise the burn wound made by a 1.2cm 
diameter stainless steel device [87] and excised the entire initial contact site of the thermal 
burn. Because peripheral injury extends radially beyond the contact area, this excision 
leaves a thin (~3mm) rim of damaged tissue. The excised areas were then treated with pre-
crosslinked hydrogels shaped to fit the size of the wounds. For dressing, a layer of 
Tegaderm® was bandaged over the treated area to hold the hydrogels in place and prevent 
desiccation.  In the second protocol, all the necrotic tissue was excised, including all grossly 
abnormal tissue which extended up to 3mm beyond the initial contact site. 
Vascularization of the entire hydrogel (i.e. throughout the entire wound bed), as 
evidenced by immunohistochemical staining for CD31, was seen by day 5 only in wounds 
that had complete excision of the burn wound.  In contrast, incomplete excision negatively 
impacted vascularization of the hydrogel during that time frame (Figure 5-3A). Hydrogel 
vascularization, quantified both as vessel density and the percentage of area covered by the 




vascular regression for the completely excised wounds, consistent with a superior healing 
process (Figure 5-3B), prompting selection of this model for use in all subsequent studies. 
We next examined the ability of the hydrogel to promote vascularization and 
subsequent vessel regression within healing wounds compared to wounds treated with 
dressing alone following complete excision of burn injured tissue. In the first week after 
excision, mean vascular density in both groups were increased at both day 5 and 7 when 
compared to baseline. However, a more rapid vascular regression was noted in hydrogel 
treated wounds. Specifically, the hydrogel treated wounds exhibited significant decrease 
in vessel density by day 14, whereas the dressing-only treated group showed no significant 
change over the same time period (Figure 5-3C). Blood flow analysis on day 14 confirmed 
a significant reduction in blood flow in the hydrogel treated wounds compared to dressing-
only treated wounds that was closer to that seen in uninjured skin (Figure 5-3D), supporting 





Figure 5-3. Wound excitement and kinetics of vascularization.  
(A) Immunohistochemistry for CD31 of wound area depicting vascular ingrowth on 
day 5 for partially excised (method 1) and completely excised (method 2). High 
magnifications of the boxed areas are shown on the right.  (B) Quantification of 
CD31 stains at of the wounds treated in both methods over two weeks N=3 per time 
point. (C) Immunohistochemistry for CD31 and quantification of vasculature over 
two week of the hydrogel-treated wounds and dressing-treated wounds over two 
weeks. N=3 per time point. (D) Laser speckle contrast images (right) and 
quantification (left) of blood flow in hydrogel-treated wounds and dressing-treated 
wounds on day 14. D= dressing-only treated wounds; H= hydrogel treated wounds. 
N=7. Scale bars are 1mm in A and C and 1cm in D. Significance levels were set at 
*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Red asterisks indicate significant 
change along time; Black asterisk indicate significant difference between the two 





5.3.3 Wound closure and re-epithelialization 
A key feature of any healed wound is complete reepitheliazation. Compared to murine 
wounds, which heal primarily by contraction, the process of wound healing by 
reepithelialization in humans is better modeled in the pig. We have examined dressing 
versus hydrogel treatment. During the treatment period, dressings were changed three times 
a week until wound closure was complete. Occasionally, this dressing change on day 5 
interrupted the integrity of the healing area, which prompted us to also examine the re-
debridement on day 5 following by re-application of hydrogel or dressing-only. Gross 
examination of the wounds at day 14 revealed a delay in wound closure in the dressing 
only treated wounds compared to hydrogel treated wounds (Figure 5-4Ai). Examining 
gross wound closure, we found that all hydrogel treated wounds appeared closed while just 
14% of dressing-only treated wounds and none of the dressing retreated wounds were 
closed (Figure 5-4Aii), resulting in wound gap in the dressing-only treated wounds and 
larger gap in the dressing retreated wounds (Figure 5-4Aiii). While all hydrogel treated 
wounds closed on day 14, all dressing-only treated wounds closed 7 days later on day 21 
post treatment, shows a 33% delay in wound closure rate (data not shown). Identification 
of the neoepithelium on masson trichrome or K14 (keratinocyte marker) stained sections 
confirmed that dressing-only treated wounds had an epithelial gap, while hydrogel- treated 
wounds were completely re-epithelialized (Figure 5-4B). A similar trend was found with 
retreated wounds where dressing-only retreated wounds had a gap in the epithelial layer 
while hydrogel retreated wounds were closed with a thick and reticulated epithelial layer 
(Figure 5-4C). As it was noted the appearance of the neoepithelium of hydrogel treated 




(i.e the percent of the reticulated epithelium in the regenerated epithelium) and the rete 
ridges [99]. We found that dressing-only treated wounds had a very low rete percentage 
and density, while hydrogel treated and retreated wounds exhibited high rete percentage 
and rete density. Consistent with a superior regenerative response, hydrogel treated wounds 
have rete density similar to healthy skin (Figure 5-4Di-ii). Finally, the hydrogel treated and 
hydrogel retreated wounds exhibited similar decrease in vessel density from day 7 to day 
14, whereas the dressing and dressing re-treated group showed no significant change over 
the same time period (Figure 5-5). Based on these results, hydrogel treatment (without the 










Figure 5-4. Wound closure and re-epithelialization. 
(A) Wounds on day 14: (i) representative wound images; (ii) percentage closed 
wounds gap and (iii) open wound area. D= dressing-only treated wounds; H= 
hydrogel treated wounds; D-R= dressing retreated wounds; H-R= hydrogel retreated 
wounds. N=7 for D and H and N=3 for D-R and H-R. (B) Wounds on day 14: (i) 
representative wound images and (ii) immunohistochemistry for K14 (upper panel; 
arrows indicate open wound) and masson trichrome stain (lower panel).  High 
magnifications of the boxed areas are shown on the right. D= dressing-only treated 
wounds; H= hydrogel treated wounds; (C) Wounds on day 14: (i) representative 
images and (ii) Immunohistochemistry with K14 (upper panel; arrows indicate open 
wound). High magnifications of the boxed areas are shown on the right. D-R= 
dressing retreated wounds; H-R= hydrogel retreated wounds. (D) Quantification of 
(i) rete percentage and (ii) rate density of day 14-treated wound. N=3. D= dressing-
only treated wounds; H= hydrogel treated wounds; D-R= dressing retreated wounds; 
H-R= hydrogel retreated wounds. Scale bars are 1cm in Ai and Bi; 1mm in Aii, Bii 
and 0.5mm in high magnification inserts. Significance levels were set at *p<0.05, 





Figure 5-5. Blood vessels following re-treatment. 
 (A) Quantification of vasculature after re-treatment up to two weeks. (B) Laser 
speckle contrast images (right) and quantification (left) of blood flow in hydrogel-re-
treated wounds and dressing-re-treated wounds on day 14. D-R= dressing only-re-
treated wounds; H-R= hydrogel-re-treated wounds. N=3. Significance levels were set 
at *p<0.05, and **p<0.01. 
 
5.3.4 Healing kinetics 
To further analyze whether the dextran hydrogel treated wounds heal in a more efficient 
manner, gene array analysis on days 5,7, and 14 post treatment was performed. In general, 
we found that there was a higher expression of inflammatory mediators at day 5, suggestive 
of a stronger inflammatory response for dressing-only treated group, compared to hydrogel 
treated wounds and which regressed as time progress (Figure 5-6A). Notably, expression 
analysis suggests a persistence of inflammation may be driven by sustained expression of 
mediators such as chemokine (CCL2) and tumor necrosis factor (TNF) in the dressing 
treated wounds compared to hydrogel-treated wounds (Figure 5-6B). Immunostaining for 
macrophage marker (MAC387) revealed an abundance of macrophages throughout the 
granulation tissue at day 5 in the dressing-only treated wounds, which decreased in density 
on day 7. In contrast, although macrophages were present in dextran hydrogel treated 
wounds, significantly less macrophages were found in the granulation tissue in both time 
points (Figure 5-6C). In the meantime, hydrogel treatment induced expression of ECM and 




with differences maintained through day 14, suggesting superior granulation tissue 
formation (replacement of the hydrogel with native matrix and fibroblasts) and more 
efficient remodeling of this matrix in hydrogel-treated wounds (Figure 5-6D). Overall, 
these results suggest that hydrogels, in comparison to treatment with dressing only, can 
promote a controlled healing response that is characteristic of a regenerative response 
including efficient resolution of inflammation, promotion of an ECM rich granulation 
tissue with accelerated vascular regression and a superior rate of reepithelialization and 


















Figure 5-6. Healing kinetics.  
(A) Wound healing gene array analysis for inflammatory mediators on day 5,7 and 
14. (B) Relative gene expression of TNF and CCL2 of the treatments on day 5,7 and 
14. (C) (left panel) Representative images of immunefluorescence stain for 
macrophage (red; nuclei in blue) and (right panel) quantification of macrophage 
density in the wound area on days 5 and 7. (D) Wound healing gene array analysis 
for ECM associated genes on day 5,7 and 14. D= dressing-only treated wounds; H= 
hydrogel treated wounds. Significance levels were set at *p<0.05, **p<0.01, 





5.3.5 Wound Remodeling and Re-innervation 
So far, we have shown that treatment with the dextran hydrogel enabled the re-
epithelialization and wound closure by day 14 accompanied by rapid inflammatory 
response, angiogenesis and vessel regression. Underneath the reepithelialized wound, 
further dermal remodeling is needed to achieve complete healing. To further examine the 
effect of hydrogel treatment on this process, we analyzed dermal ECM protein composition 
at day 40 post treatment. We found that mature collagen fibers could be observed 
throughout the neodermis of hydrogel treated wounds, while dressing treated wounds had 
mature collagen fibers primarily at the periphery of the wounds as evidenced by Masson 
trichrome staining (Figure 5-7A and Figure 5-7Bi). Moreover, we found that elastic fibers 
were present in the periphery of hydrogel-treated wounds but were significantly reduced 
in dressing treated wounds (Figure 5-7Ci-ii), suggesting that hydrogel treated wounds were 
at a more advanced stage of remodeling compared to dressing treated wounds at the same 
time.  
In addition to significantly increased deposition of collagen and elastin fibers in 
hydrogel treated wounds compared to controls, gene analysis revealed significant 
upregulation of KAL1 and Laminin alpha 2 mRNA expression (Figure 5-8A). These two 
genes are associated with neuron guidance [189-191] indicating a potential greater 
peripheral neuron infiltration.  To assess whether dextran hydrogel promote re-innervation 
of healing burn wounds, the presence of peripheral nerve ingrowth was assessed by 
immunoflourecence for the neuronal marker protein gene product 9.5.  This data shows 




peripheral nerve ingrowth to the central portion of the wounds was observed only in the 





Figure 5-7. Remodeling of third-degree burns.  
(A) Representative images of Masson Trichome histological stains of d40 hydrogel 
treated wounds or dressing-only treated wounds. High magnifications of the boxed 
areas shown below. (B) (i) Quantification of collagen fiber % in the wounded area 
(indicated in the white dotted circle in A). (ii) Quantification of elastin fiber density 
in the dermis area adjacent to the epidermis. N=4 (C) Representative images of 
Verhoeff–Van Gieson histological stains of d40 hydrogel treated wounds or dressing-
only treated wounds. High magnifications of the color-coded boxed areas near the 
epidermis in A are shown.  Yellow boxes are at the wound edge and green boxes are 
at the middle of the wound. Yellow arrows indicate mature elastin fibers. Significance 
levels were set at *p<0.05, **p<0.01 and ***p<0.001. Scale bars are 1mm in A and 






Figure 5-8. Reinnervation of third-degree burns.  
(A) Gene array analysis for wound remodeling associated genes of tissue from 
hydrogel treated wounds versus dressing-only re-treated wounds. (B) 
Immunoflorescent staining for neuronal fibers (indicated by white arrows) at the 
edge of the wounds and in the middle of dressing -treated (upper panel) and 
hydrogel-treated (lower panel) treated wounds. Neurons (PGP9.5) in green, blood 








Full- or split-thickness skin grafting is the current gold standard for wound closure 
following severe burn wound injury, but not only do these grafts have a limited availability, 
they can also leave thick scars and distorted contractures. Given these suboptimal 
functional, aesthetic and financial outcomes, significant research efforts have focused on 
developing cell-based skin substitutes, but there are many hurdles for these biological 
products to attain approval before reaching clinical use. A few synthetic substitutes have 
made their ways to the market, but most provide only a temporary barrier until autografts 
are available for permanent closure [192]. To the best of our knowledge, there is no 
synthetic product currently indicated for treating third-degree burns.  
In the current study, we have tested our initial findings which revealed proregenerative 
properties of dextran-based hydrogel in a murine burn wound model by examining the 
vulnerary capacity of these hydrogels as a treatment for third-degree burns in pigs towards 
their potential use in clinical studies. The dextran-based hydrogels have been shown to 
accelerate wound healing in subcutaneous and burn wounds in murine studies [87] 
suggesting that they promote a regenerative response post injury. However, the murine 
cutaneous wound healing model has several known limitations as a translational wound 
healing model, particularly for burn wound therapies.  
We began by establishing a reproducible protocol for creating third-degree burn 
wounds in adult pigs. In murine studies, a 100°C heat source is sufficient for creating a 
full-thickness burn wounds, and others have also used this temperature in adult pigs as well 




burns in adult pigs, we found that 200°C provides the sufficient heat for the wounds to 
progress into a full-thickness dermal damage within 48 hours. This progression of burn 
injury after the initial heat damage is also seen in human burn patients [193].  
We then moved on to optimize the dextran hydrogel treatment procedure by examining 
the kinetics of the vasculature inside the wounds.. Angiogenesis followed by vessel 
regression plays a crucial role in wound healing progress [194, 195], but compared to 
excisional wounds, sever burn wounds exhibit impaired and slower neovascularization, 
potentially due to delayed mobilization of circulating angiogenic cells [196, 197]. 
Therefore, we theorized that treatment methods that can facilitate rapid angiogenic 
response followed by fast vascular regression would be great candidates for wound healing 
therapies. In order to simulate the clinical settings where the necrotic tissues are either 
debrided completely or partially, we treated the wounds with the hydrogels after either 
completely or partially excising the burned skin and tested which method provides better 
healing results. In terms of treating the wounds with the dextran hydrogels, we found that 
completely excising the necrotic skin accelerated the infiltration of blood vessels into the 
treated areas and more profound regression of the neovessels over time, indicating better 
healing kinetics.  
Comparing this treatment method to the dressing-only treated wounds, wound closure 
was accelerated in dextran-based hydrogel treated wounds, and the healing occurred in a 
regenerative fashion, characterized by a rapid angiogenic response followed by vascular 
regression. Furthermore, rapid re-epithelialization and high quality of epithelium formed 
were present in the dextran-based hydrogel treated wounds compared to control wounds. 




treatment with the hydrogel allowed fast re-epithelialization, demonstrating the robustness 
of the hydrogel treatment and its potential in the clinics. The rapid wound closure in the 
dextran treated burns may be due to combination of factors including the moist 
environment provided by the hydrogels, which leads to a more efficient re-epithelialization 
and faster stromal cell migration [198], excellent mechanical properties along with charged 
functional groups of the dextran hydrogel [85], and the high angiogenic capability of the 
dextran hydrogel [85-87] result in an overall quicker and better epidermis reconstruction. 
The rapid onset and regression of the inflammatory response plays a crucial role in 
coordinating the process of wound healing [149]. Examining inflammatory signals over 
time in both hydrogel and dressing-only treated groups, we found higher expression of 
proinflammatory mediators on day 5 in the dressing treated wounds compared to the 
hydrogel treated wounds suggesting persistent inflammatory response. While the necessity 
of inflammatory response in wound healing is debated [199, 200], in the context of 
biomaterial-induced healing, appropriate timings and durations of acute and chronic 
inflammatory responses would be needed for better healing results [201]. Gene array 
analysis on days 5, 7, and 14 revealed lesser inflammatory response in the hydrogel treated 
group than in the dressing-only treated group. Immunohistochemistry showed high density 
of macrophages in the dressing treated wounds on day 5, which regressed by day 7. In 
contrast, only few macrophages in the dextran hydrogel treated wounds could be observed 
during these time points. Since inflammatory cells, especially macrophages, secrete 
essential cytokines and growth factors necessary for angiogenesis and stromal cell 
migration [202], the elevated neovascularization followed by early vascular regression in 




During wound remodeling stage, the granulation tissue is being remodeled in order to 
reconstruct the loose regenerated dermis and strengthen the repaired tissue [149]. The 
severity of scarring depends on the amount and the organization of the secreted ECM 
during this phase. Therefore, an ideal skin substitute would induce high ECM deposition 
and organized crosslinking of ECM fibers in order to minimize scarring. Gene array 
analysis indicated that hydrogel treatment induced the expression of ECM and remodeling 
genes on days 7 and 14. Indeed, after 40 days of treatment, hydrogel treated healing wounds 
showed higher density of collagen compared to the dressing-only group, and the structure 
of the newly deposited collagen observed in the hydrogel treated wounds showed higher 
organization. In addition, elastin fibers, which is usually poorly restored in scars [203], 
were deposited in higher density in hydrogel treated wounds. Together with collagen, the 
regeneration of elastin provides favorable fiber frameworks for the later phase of wound 
healing [202].  
Since the skin is also a highly sensitive organ, after a deep burn injury, cutaneous nerves 
regenerates from the wound bed with the new nerve fiber migration, or collateral sprouting 
from the adjacent skin [191]. In fact, burn victims often suffer permanent sensory deficits 
from abnormal sensation to chronic pain [204-206]. In addition, these deficits are more 
pronounced following skin graft [207]. As a result, neuron regeneration poses a major 
challenges in order to improved patients’ quality of life by restoring its sensory perceptions 
of the regenerated skin. We found that dextran hydrogel treatment promoted nerve 
ingrowth into the regenerated skin with the nerve fibers presents close to the center of the 
wound on day 40. In contrast, we were unable to locate nerve fiber in the dressing treated 




remolding, but also improved the re-innervation of the repaired wound. However, further 
examination of the nerve fiber will be need to identify which type and maturity of nerve 
fibers as well as the mechanism of the recruitment. While we examined our samples, we 
found that these nerve fibers often time co-localized with the blood vessels. We thus 
speculate that perhaps the enhanced neovascularization during hydrogel treatment as well 
as more rapid re-epithelialization consequently contributed greater neural ingrowths during 






Consistent with our previous murine study, we observed regenerative wound healing 
induced by the hydrogels in adult pigs. Although there are many similarities between pig 
and human skins, clinical testing with burn patients is still necessary as some of the 
physiological differences between the species may affect the healing timeline and also the 
quality of the healed skin. For example, pig skin is much less prone to infection and 
contamination compared to human skin [175]. As the wounds infected by the external 
environment may slow down the healing process and result in serious scar formation, 
thorough debridement of necrotic tissue is essential to optimal hydrogel response when 
translating the therapy in a clinical setting. In addition, to reduce infection occurrence, the 
dextran hydrogels can be embedded with antimicrobial agents, similarly to our previous 
work with cytokines encapsulation [86]. 
Our translational study establishes a robust protocol for injury and hydrogel treatment 
of third-degree burns in a porcine large-animal model and thus paves the way for their use 
in clinical studies. Encouragingly, treating the burned, full-thickness wound with our 
dextran-based hydrogel allows functional regeneration of the tissue through fast 
neovascularization and epithelial wound closure. In addition, the dextran hydrogel 
promotes more efficient dermis reconstruction and enhanced re-innervation.  The absence 
of drugs or cells may allow our therapy to avoid numerous regulatory hurdles and speed 
up its translation into the clinics [208, 209]. Overall, our findings support the dextran-based 
hydrogels as an ideal candidate of next generation of low-cost, off-the-shelf and readily 
available treatment of a range of dermal injuries, which translates to enhance wound care 








6 Thesis conclusions and future work 
 
6.1 Conclusions 
Angiogenesis is essential during wound healing and also plays critical roles in 
various diseases. Using biomaterials as an accelular scaffold to study vascular restoration 
or use it as a scaffold to induce vascular network in vitro towards vascularized constructs 
has provided an alternative approach for wound repair and tissue regeneration. We utilized 
two types of bioactive hydrogel systems. Dextran is functionalized with amine groups and 
further crosslinked using UV irradiation with PEGDA for vascular restoration. Hyaluronic 
hydrogel modified with biding adhesive domain RGD and MMP cleavable sites, are 
designed to induce vascular network formation in vitro from encapsulated human vascular 
cells.  At the same time, the tunability of our hydrogel system provide a valuable tools and 
allow us to adapt three dimensional (3D) tissue culture models that recapitulate aspects of 
the tumorogenic in vivo microenvironment to study cancer progression in vitro.  
For example, both hypoxia and matrix stiffness were shown to promote tumor 
growth.  In Chapter3, using the HA hydrogel systems and mathematical modeling we 
found that hypoxic activation of HT1080 cells encapsulated in the 3D HA hydrogel enables 
better cell survival through autophagy and supports greater EC sprouting with lesser extent 
in matrix stiffness effects on the cancer cells. Potential uses for this system includes 




to external stresses such as inflammatory cytokines, and selectively impeding cancerous 
processes.  
We have also previously engineered this modular HA hydrogel culture system to 
engineer a functional microvascular network from EPCs, EVCs derived from the hiPSCs 
that are comprised of VEcad+ and PDGFRβ+ cells (ie endothelial cell and pericytes, 
respectively.) In Chapter4, we first developed an immunodeficient rodent DFU models. 
We further successfully engineered vascularized constructs by using various vascular cell 
sources within the HA hydrogel which can be used for transplantation treatment. We show 
that all vascularized constructs enhances faster wound closures compared to none treated 
wounds or wounds treated with HA alone. We have demonstrated a potential therapeutic 
strategy using stem cell derived vascularized scaffold to treat diabetic foot ulcers. 
Lastly, we investigated another deep tissue injury model. Burns, a dermal wound 
affecting millions, often heals as fibrous scar tissue.  We have utilized acellular bioactive 
polysaccharide hydrogels with tunable properties suitable for promoting vascularization 
and healing in treating full thickness dermal wounds. Dextran polymer is modified with 
functional ethylamine groups (AE) designed to promote interactions with surrounding host 
tissue. Burn wounds treated with dextran hydrogels have showed enhanced re-
epithelialization, hair follicle recruitment and neovasculargenesis during the healing 
process in rodent model. In Chapter5, we extended our dextran hydrogel treatment in a 
porcine model for full thickness burn injury. Our translational study establishes a robust 
protocol for injury and hydrogel treatment of third-degree burns in a porcine large-animal 
model and at the same time treating the burned, full-thickness wound with dextran-based 




epithelial wound closure. In addition, the dextran hydrogel also promotes more efficient 
dermis reconstruction and enhanced re-innervation.   
6.2 Suggestions for future works 
The work presented in this thesis demonstrates our ability to utilized bioactive 
hydrogel scaffolds to study microenvironmental effects on vascular diseases and at the 
same time, engineering vascularized constructs to treat deep tissue injuries. However, 
further improvement of our systems could allow us to better study the ECs involvement in 
tumorigenesis as well as engineered a more matured functional vascularized constructs for 
therapeutic treatment.  
For instance, we demonstrated tumor cell angiogenic potential using 2D assay. 
However, co-cultures of ECs and tumor cells in 3D could provide insights on how these 
wound interact with each other during tumorigenesis which could provide a robust in vitro 
platform for drug screening. Also, further modification of the polymer would allow us to 
investigate larger range of elastic modulus and we could scan through a library of cancer 
cell lines or the same tumorigenic cell source with different metastatic potential investigate 
the cellular behaviors to gain more insights on potentials therapeutic strategy.   
From the regenerative medicine perspective, fostering from the biology 
advancements, co-cultured of mature cell line such as vascular smooth muscle cell with 
sequential growth factors release strategy may improve our in vitro vascularized constructs.  
However, one of the drawback of our current systems is that we lack reporter signal for our 
multipolar stem cell derived EVCs. Developing a reporter signaling strategy could allow 




vasculargenesis and further modulate the sequence of events in real time when 
encapsulated in the constructs in vitro in 3D or in vivo.  
At last, we could also incorporate inflammatory cells such as macrophages since 
during the course of wound healing, inflammation is followed by onset of angiogenesis 
and the regression of the inflammatory signals maturation of the recruited blood vessels. 
It’s now accepted that macrophages are bi polar where one promote inflammation and the 
other signals maturation and stabilization of the blood vessels. By understand how these 
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